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ABSTRACT

ROLE OF FGFR4 GLYCOSYLATION AND PROCESSING IN

CHOLANGIOCARCINOMA SIGNALING AND PROGRESSION
Andrew J. Phillips, Ph.D.
University of Nebraska, 2021
Supervisor: Justin Mott, M.D., Ph.D.
Cholangiocarcinoma is a cancer of cholangiocytes, or epithelial cells lining the biliary
tract. It is associated with a poor prognosis and additional therapeutic treatments are
needed to help patients affected by this disease. Fibroblast growth factor receptor 4
(FGFR4) is receptor tyrosine kinase that is involved in various physiologic and
pathologic processes. TCGA analysis of thirty different tumor types showed the highest
FGFR4 mRNA levels in cholangiocarcinoma. At the protein level, FGFR4 was observed
in the majority of cholangiocarcinomas screened and, higher levels were associated with
a poorer prognosis. FGFR4 is an N-linked glycosylated receptor tyrosine kinase that we
show here is modified through a cleavage process called regulated intramembrane
proteolysis, where the intracellular kinase domain is released from the plasma
membrane. Both glycosylation status and regulated intramembrane proteolysis have
been shown to be involved in modifying cancer phenotypes. As such, a multifaceted
approach to FGFR4 signaling was taken to look at the role of glycosylation on FGFR4
signaling and processing. Additionally, the regulated intramembrane proteolysis process
was studied, and we identified a new form of FGFR4, R4-ICD, with a signaling role in
cholangiocarcinoma cells.
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CHAPTER 1: INTRODUCTION

2

The focus of this dissertation is the receptor tyrosine kinase, FGFR4. Studies
here report on glycosylation and proteolytic processing events that affect FGFR4
function, and how this information can be used to help patients with cholangiocarcinoma,
a rare liver cancer with a dismal prognosis. The following sections introduce relevant
aspects of cholangiocarcinoma, receptor signaling, and post-translational processing.

Cholangiocarcinoma
Cholangiocarcinoma is a cancer of the cholangiocytes, or the epithelial cells that
line the biliary tree [1]. The biliary tree is a branching system of bile ducts within and
outside of the liver that carries bile produced in the liver to the gallbladder or duodenum.
Cholangiocarcinoma can be either intrahepatic or extrahepatic, depending on where the
tumor originates. A common form of extrahepatic cholangiocarcinoma, called the
Klatskin tumor, occurs at the branching point of the left and right hepatic ducts or the
hilum, and, if detected early enough, can be treated through orthotopic liver transplant in
addition to adjuvant and neoadjuvant therapies [2]. Highly selected patients who receive
a transplant for cholangiocarcinoma treatment have a 5-year survival similar to that of an
individual receiving a liver transplant for other reasons: roughly 65% (vs 75% for all liver
transplants) [2]. However, the majority of cholangiocarcinoma patients are not transplant
candidates and have a poor prognosis, with 5-year survival rates at or below 10% [1]. In
part, this is due to the silent nature of the tumor when it is in its early stages. Individuals
seldom present with symptoms until the tumor has grown and metastasized, and even
then, symptoms can be nonspecific, for example: abdominal pain, weight loss, fatigue,
and loss of appetite. At later stages, patients may show signs and symptoms of biliary
obstruction, such as jaundice, scleral icterus, and severe itching.
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Several known risk factors exist for cholangiocarcinoma, including primary
sclerosing cholangitis, hepatolithiasis, bile duct cysts, toxic agents (e.g., Thorotrast), and
liver fluke infections [3]. Due to cultural and risk factor-associated differences, the
incidence of cholangiocarcinoma varies greatly by geographic region. For example, the
consumption of raw or semi cooked seafood in Southeast Asia leads to liver fluke
infections resulting in a much higher prevalence of cholangiocarcinoma in that part of the
world; approximately 33.4/100,00 in Thai men and 12.3/100,000 in Thai women [3]. In
the United States, however, liver fluke infestation is not endemic, and the prevalence of
cholangiocarcinoma is estimated at 0.5-2.0/100,000 [4, 5]. The majority of cases in the
US occur sporadically or as a result of primary sclerosing cholangitis. Still, it is the
second most common primary malignant liver cancer.
Medical treatment options for patients with cholangiocarcinoma are quite limited.
The current typical treatment is gemcitabine plus cisplatin [6]. Compared with
gemcitabine alone, patients on the dual therapy showed a small but measurable 3.6
month increase in survival on average. Because the clinical benefit of current therapeutic
options is so limited in patients with cholangiocarcinoma, patients are encouraged to
take advantage of clinical trials whenever possible. In the meantime, finding new
therapeutic targets in cholangiocarcinoma remains a top priority.

Receptor tyrosine kinases
Receptor tyrosine kinases, or RTKs, are a large group of type 1 transmembrane
proteins that contain an N-terminal extracellular ligand binding domain, a helical single
pass transmembrane domain, and a C-terminal intracellular kinase domain. In humans,
there are 58 known RTKs, however, these proteins are very well-conserved across
species. They play a variety of different physiologic roles, but importantly can also
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contribute to disease states, including diabetes, inflammation, vascular changes and
cancer [7-9].
Mechanistically, canonical RTK signaling occurs first through ligand binding.
Upon ligand binding to the extracellular domain of the receptor, conformational changes
occur which allow for protein dimerization. It should be noted that some RTKs
oligomerize even in the absence of ligand, for example the insulin receptor and IGF1
receptor which are expressed as disulfide-linked dimers. In either case, conformational
changes follow ligand binding, leading to receptor tyrosine kinase domain activation via
transphosphorylation, in which the tyrosine kinase domains of dimerized RTKs
phosphorylate one another [7, 10]. Prior to ligand binding, an individual tyrosine kinase
domain of an RTK has an autoinhibitory conformation to prevent tyrosine
phosphorylation and subsequent downstream signaling from occurring. The structural
determinant of this inhibitory conformation varies greatly among RTKs. For example, in
FGFR1, residues in the activation loop do not specifically interfere with ATP binding, but
rather seem to stabilize the inactive form. This is contrary to the insulin receptor, where
ATP binding is directly (sterically) blocked in the inactive form of the receptor [11]. When
ligand binding and dimerization occur, changes in the tyrosine kinase domain lead to
destabilization of the autoinhibitory region and in some cases, the inhibitory portion of
the juxtamembrane region [8, 12].
Dimerization of ligand-bound receptors has been hypothesized to occur through
one of several different mechanisms: bivalent ligands pulling or crosslinking two
receptors together, ligand-ligand interactions (where the two receptors do not touch),
receptor-receptor interactions (where the two ligands do not touch) or some variation of
the two extremes. In the case of fibroblast growth factor receptors (FGFRs), several
models have been proposed. In one case, x-ray crystallography demonstrated the
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dimerization of two FGFR1c receptors through interaction with two FGF2 molecules and
two cofactor molecules (heparin) in a 2:2:2 fashion. In this model, the receptors were in
direct contact with one another. Each FGF molecule interacted with both receptors but
each formed a major interaction with one and a minor interaction with the other such that
each receptor had one FGF tightly bound and one FGF more weakly bound. Heparin
was in direct contact with both ligands and both receptors at the second
immunoglobulin-like loop (IgII) [13]. An alternate crystal structure showed heparin
serving as the bridge in connecting two separate FGF1/FGFR2 complexes. In this
situation, the 2:2:2 ratio was disrupted [14]. Variations seen between experiments may
simply be due to the variations among FGFRs and FGFs (i.e., FGF1 versus FGF2),
availability of cofactors, or environmental conditions (temperature, salt concentration,
pH, etc.). Notably, FGFR4 binds ligand in cooperation with Klotho coreceptors and is not
heparan sulfate-dependent. Indeed, FGF19, which preferentially activates FGFR4, is an
endocrine FGF due to its lack of affinity for heparan sulfate. While ligand binding to the
extracellular domains promotes dimerization, the transmembrane and intracellular
domains also have the ability to form dimeric contacts. In either case, dimerization
ultimately leads to receptor activation.
Once transphosphorylation is complete, specific phosphotyrosine (pY) residues
in the kinase domain can directly bind proteins containing Src-homology 2 (SH2)
domains or phosphotyrosine binding domains. Alternatively, docking proteins (FRS2,
IRS1, Gab1) may directly bind the phosphotyrosine residues in the activated tyrosine
kinase domain and subsequently recruit proteins containing SH2 or phosphotyrosine
binding domains to trigger the activation of a signal cascade [7, 9, 10, 15-17]. RTK
signaling also leads to receptor ubiquitination and subsequent internalization and
redistribution or lysosomal degradation of the receptor, creating a process for negative
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feedback and means for regulating signaling [18]. FGFR4 has been shown to undergo
less ubiquitination and is primarily endocytosed and recycled, whereas FGFR1-3 tend to
have higher levels of ubiquitination and primarily undergo lysosomal degradation [19].
Perhaps this is not surprising, but of the RTK FGFR proteins, FGFR4 contains the
fewest number of lysine residues intracellularly (FGFR1: 29, FGFR2: 30, FGFR3: 26,
FGFR4: 16). Lysine residues are targeted by E3 ubiquitin ligases for ubiquitination.
Accumulation of ubiquitin molecules can modify protein function and signaling but can
also serve as a tag for protein degradation. Lysine to arginine mutations within the
intracellular domain of FGFR1 prevented FGFR1 from entering the lysosome and
promoted its recycling [19].
More recent studies have shown that RTKs can signal through a process called
regulated intramembrane proteolysis (RIP). In RIP, a majority of the ectodomain—the
extracellular portion of the protein—of an integral membrane protein is cleaved by a
sheddase, a generic term for a group of proteases (typically a disintegrin and
metalloprotease protein, ADAM) that cleave integral membrane proteins at the
juxtamembrane region of the ectodomain. The remaining portion of the ectodomain is
typically 12-35 amino acids in length, although this number may vary from source to
source [20]. This shedding event alters the conformation of the remaining receptor which
allows γ-secretase to cleave the receptor within its transmembrane domain (Figure 1).
From there, the released intracellular portion of the protein can serve a variety of
different functions. The intracellular fragment can translocate to the nucleus, as seen
with Notch, ERBB4, FGFR3, PTK7, and RYK [21-24]. Additionally, the intracellular
domain (ICD) can localize to the mitochondria, as seen with ERBB4 ICD, where it serves
as a pro-apoptotic signal [25, 26]. EPHB2 ICD has been shown to phosphorylate and
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TM

S1: sheddase

S2: γ-secretase

TM

P

Figure 1. Regulated intramembrane proteolysis of receptor tyrosine kinases.
A receptor tyrosine kinase is shown with three extracellular Immunoglobulin-like
loops, a transmembrane (TM) domain, and an intracellular kinase domain. In
regulated intramembrane proteolysis (RIP), an initial cleavage event, S1, is
proceeded by a secondary cleavage event, S2. S1 cleavage is frequently catalyzed
by sheddase proteases like ADAM proteins, and S2 cleavage is catalyzed by γsecretase.
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modulate the localization of other membrane receptors [27]. In cancer, ligand-induced
cleavage of EPHB2 by MMP proteins was shown to initiate cell repulsion, allowing for
cell migration or metastasis [28]. Alternatively, preventing AXL cleavage promoted
resistance of lung adenocarcinoma cells to treatment by Erlotinib [29]. MET ICD appears
to simply undergo rapid degradation [30]. With these examples in mind, it becomes quite
clear that there is a high degree of variability regarding the role/function of the released
intracellular domain following RIP, including relocalization to activate new signaling or
transcription, or alternatively the ICD is degraded to halt signaling.
In cancer, several different alterations to RTK pathways and signaling can
promote malignancy. These alterations include genomic amplifications, gain of function
mutations, autocrine activation, or chromosomal rearrangements leading to fusion
proteins [31]. As such, a number of targeted therapeutics are designed to inhibit RTKs.
RTK inhibitors prevent phosphorylation of downstream targets by directly inhibiting RTK
phosphorylation or by preventing RTKs from interacting with their binding partners. Both
forms of inhibition can occur competitively or allosterically. Commonly, drugs have
targeted the ATP binding site; however, this binding site is conserved in RTKs and
frequently results in drugs having off target interactions. While there are situations where
a drug interacting with more than just its intended target can increase its efficacy (a
notable example being the multi-kinase inhibitor sorafenib with efficacy in hepatocellular
carcinoma), targeting multiple kinases can potentially increase the toxicity associated
with a drug [32]. As such, the development of drugs targeting allosteric sites has become
increasingly more common, as these sites can produce conformational changes in the
ATP binding pocket, but are less highly conserved between receptors and therefore,
have higher variability in structure. Allosteric targeting of low conserved sites ultimately
allows for general higher selectivity in these drugs. Selectivity has been achieved
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through other approaches as well. In the case of FGFR4, a unique cysteine residue at
position Cys-552 was noted and an inhibitor that binds the ATP binding pocket was
modified to have an accessible ‘warhead’ domain for covalent Cys modification (Hagel et
al., 2015, Cancer Discovery). This led to the development of Fisogatinib (BLU554),
which binds FGFR4 with affinity 100-fold higher than FGFR1 and 1000-fold higher than
FGFR2 and FGFR3 [33].

FGFR family of proteins and cancer
FGFRs are a subfamily of receptor tyrosine kinases that interact with fibroblast
growth factors. These receptors/ligands have been shown to play a role in embryonic
development, tissue repair, proliferation, migration and cell survival. Structurally, these
proteins consist of three extracellular Ig-like domains at their N-terminus, a single pass
transmembrane domain, and an intracellular protein kinase domain (C-terminus).
Alternative splicing can occur in FGFRs 1-3 and is often tissue-specific to alter affinity for
different FGFs [34]. Ligand-receptor binding among FGFs and FGFRs can occur with a
good deal of cross-activation. Cofactors required for receptor activation help to promote
tissue-specific receptor activation and reduce promiscuity. Most FGFs use heparan
sulfate proteoglycans as their cofactors, whereas FGF19/15, FGF21 and FGF23 use
klotho proteins as their coreceptors [35, 36]. Beta klotho (KLB) serves as a coreceptor
for FGF19/15 and 21, while alpha klotho (KLA) serves as a coreceptor for FGF23 [37,
38]. In addition to requiring different cofactors, the FGF19/15 subfamily of proteins
(FGF19/15, FGF21 and FGF23) participate in hormonal- paracrine- and autocrinesignaling.
FGFR1 and FGFR3 have previously been demonstrated to undergo proteolytic
cleavage in which the intracellular kinase domain is cleaved from the full-length receptor.
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In 1996, Levi et al. demonstrated selective activity of MMP2 on FGFR1 (in the presence
or absence of FGF), which prompted the release of an extracellular domain capable of
binding FGFs. Cleavage was shown to take place between Val-368 and Met-369 on the
extracellular side of the receptor near the transmembrane region [39]. Ten years later,
Loeb et al. demonstrated that granzyme B cleaved FGFR1 intracellularly between
residues Asp-432 and Ser-433 [40]. Granzyme B-mediated cleavage of FGFR1 resulted
in nuclear localization of FGFR1’s intracellular kinase domain [41]. FGFR3 undergoes
ligand-induced RIP following receptor endocytosis. This S1 cleavage event is
metalloproteinase-independent for FGFR3. A second cleavage event, S2, occurs via γsecretase activity and releases the intracellular kinase domain, which then translocates
to the nucleus, like the FGFR1 intracellular domain [22, 42].
Germline mutations in FGFRs can lead to congenital conditions such as Pfeiffer
syndrome (FGFR1 or FGFR2), Crouzon syndrome (FGFR2 or FGFR3), and
achondroplasia (FGFR3) to name a few [43] [44, 45]. These conditions are associated
with increased kinase activity and unregulated signaling, resulting in recognizable clinical
developmental syndromes. Somatic mutations and changes in expression of FGFRs
have been observed to play a role in the development and progression of numerous
types of cancer. A screening study that looked at 4,853 tumor samples showed FGFR
alterations in 7.1% of samples. Of the samples that showed alterations, 66% were
amplifications, 26% were mutations and 8% were rearrangements. FGFR1 was most
commonly altered, and FGFR4 was least commonly altered, with roughly a seven-fold
difference between the two [46]. FGFR1 has been shown to promote tumorigenesis and
progression in various cancers including: gastric, prostate, breast, lung, and colon
cancer [47-50]. FGFR1 gene amplification is more common in cancers than are
mutational changes to the protein. FGFR1 gene amplification is observed in
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approximately 20% of squamous-type non-small cell lung carcinomas, 5-7% of small cell
carcinomas, and is very rarely observed in lung adenocarcinomas [46, 51, 52]. FGFR1
fusions are quite rare in solid tumors; however, they have been observed sporadically in
gastrointestinal stromal tumors, breast cancer, glioma and glioblastoma, with various
fusion partners involved. FGFR2 is the FGFR most commonly involved in fusion
mutations. Numerous fusion partners exist for FGFR2, and these mutations are
commonly observed in cholangiocarcinoma (8-13%) [53]. FGFR2 fusions have also
been observed infrequently in colorectal cancer and hepatocellular carcinoma. Point
mutations that result in constitutive activation of FGFR3 are common in bladder cancer
(66.6% have an S249C mutation in the extracellular domain, which promotes ligandindependent receptor dimerization) [54]. FGFR3 fusion mutations are common in
glioblastoma and bladder and lung cancer. In contrast to FGFR1 and FGFR2, most
fusions with FGFR3 occur with a common fusion partner, transforming acidic coiled coil
3 protein (TACC3), and consist of the FGFR3 N-terminal, transmembrane, kinase and
kinase insert domains fused to the TACC3 coiled coil domain to produce constitutively
active signaling through the FGFR3 kinase domain [50, 55, 56]. In addition to the
cancers described previously, FGFR mutations have been observed in a number of
other tumors, including gliomas, head and neck squamous cancer, lung squamous cell
carcinoma, and cervical cancer. FGFR4 activating mutations are rarely seen, but can
occasionally be identified in rhabdomyosarcomas and other pediatric cancers. FGFR4
fusion mutations have only recently been discovered in non-small cell lung cancers [50].
FGFR inhibitors have been and are currently being tested in clinical trials.
Several of these inhibitors target FGFR1-4 with little selectivity (Pozopanib HCL,
Erdafitinib, Futibatinib, Derazantinib, LY2874455) or target FGFR1-3 with much less
affinity for FGFR4 (Infigratinib, Pemigatinib, Rogaratinib, AZD4547, Debio 1347).
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Fisogatinib is an FGFR4-selective inhibitor. Currently, anti-FGFR drugs are primarily
being used to treat urothelial cancer or cholangiocarcinomas which harbor FGFR2
fusions [57].

FGFR4
Like the other FGFRs, FGFR4 is composed of three extracellular Ig-like domains,
a helical transmembrane domain, a juxta-membrane region, and a protein tyrosine
kinase domain. Unlike other FGFRs, the extracellular domain of FGFR4 is not
alternatively spliced [58, 59]. FGFR4 undergoes N-linked glycosylation, but glycosylation
does not appear to be necessary for proper folding of the extracellular domain or for
ligand binding [60, 61]. Sequence analysis of human full length FGFR4 shows five
possible sites for N-linked glycosylation, that can exhibit high-mannose or complex-type
(mature) glycosylation [62]. Potential glycosylation sites are identified as an asparagine
(Asn) residue followed by any amino acid except proline, and then a serine or threonine.
Previous studies have identified terminally glycosylated FGFR4 (complex-type) as the
form primarily involved in signaling [62]. It is likely the complex-type glycoform of FGFR4
is the primary signaling form, because it has been fully processed through the Golgi and
delivered to the plasma membrane where ligand-receptor interactions occur.
Glycosylation plays an essential role in Notch function and ligand binding [63] and may
play a role in FGFR4 function and ligand binding as well.
Under physiologic conditions, FGFR4 serves as a regulator of bile acid synthesis.
Bile acids are produced and secreted by hepatocytes into the biliary tree and small
intestine, then reabsorbed in the ileum and recycled back to the liver via enterohepatic
circulation [64]. The ileum also secretes the hormone, FGF19, in response to bile acid
reabsorption. Bile acids enter the epithelial cells of the ileum and activate the nuclear
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bile acid receptor, FXR, increasing FGF19 production and secretion. FGF15 is the
mouse ortholog of human FGF19, so sometimes this protein is referred to collectively as
FGF19/15. FGF19 secreted from intestinal epithelial cells circulates via the portal
circulation to the liver, serving as a negative regulator of bile acid production by binding
FGFR4 expressed on hepatocytes. Thus, FGFR4 is strongly expressed in the liver. We
have observed FGFR4 protein present in hepatocytes but not in normal bile duct
epithelial cells (cholangiocytes) in the liver (Mohr et al., unpublished observations).
In malignancy, FGFR4 signaling has been shown to promote cell proliferation
and inhibit apoptosis through the MAPK/ERK, AKT and STAT3 pathways, among others.
In breast cancer, FGFR4 activation of the MAPK/ERK pathway inhibited apoptosis by
increasing the expression of Bcl-xL [65, 66]. In cholangiocarcinoma, we found that
FGFR4 increases XIAP protein expression to inhibit apoptosis (Mohr et al.,
unpublished). Increased FGFR4 expression and/or mutation in cancer has been linked
to poorer overall prognosis [67-74]. Mutations in FGFR4 are not known drivers of
cholangiocarcinoma, but we have observed elevated FGFR4 mRNA and protein
expression in the majority of human cholangiocarcinoma samples when compared to
normal cholangiocytes.
FGFR4 is the primary receptor for FGF19, itself a tumor driver [75, 76]. Over 3%
of intrahepatic cholangiocarcinoma patients show FGF19 genomic amplification [77].
Alternatively, FGFR4 expression has been observed in a majority of cholangiocarcinoma
tumors, and its expression correlated with a poor prognosis [68].
FGFR4-selective inhibitors, BLU9931 (and analog, Fisogatinib/BLU-554), and
H3B-6527 irreversibly bind a unique cysteine residue located at position 552, adjacent to
the ATP-binding pocket, and inhibit FGFR4. Upon testing, BLU9931 was found to be
potent and showed preferential inhibition of FGFR4 in cell free experiments: FGFR4
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IC50: 3 nM, FGFR1 IC50: 591 nM, FGFR2 IC50: 493 nM, FGFR3 IC50: 150 nM [78].
Fisogatinib, a structural analog of BLU9931, is currently in phase II clinical trials for the
treatment of hepatocellular carcinoma. Because of FGFR4’s rapid turnover in
hepatocellular carcinoma, a reversible, FGFR4-selective inhibitor approach was
proposed, leading to the development of FGF401/Roblitinib. The covalent irreversible
inhibitor was not available for newly synthesized FGFR4 while a reversible inhibitor
should not be consumed and can act on newly made FGFR4. In short, FGFR4 is being
rapidly synthesized and degraded, and each molecule of the irreversible inhibitor only
functions for as long as the receptor exists. With a reversible inhibitor, the drug can have
a prolonged effect by avoiding degradation with the receptor. FGF401/Roblitinib has an
IC50 of 1.1 nM for FGFR4 and demonstrated a 1000-fold selectivity over a panel of 65
other kinases [79].
Similar to what was observed with FGFR1 [39, 40] and FGFR3 [22], recent data
has shown that FGFR4 is proteolytically cleaved through regulated intramembrane
proteolysis [60, 80] (see also our results in Chapter 4), leading to the release of the
intracellular domain. Merilahti et al. demonstrated that γ-secretase inhibition altered
FGFR4 processing, and indirectly showed that an ADAM protein may be involved in
proteolysis. Those studies did not characterize the regulated proteolysis or function of
the released intracellular domain. Here, we provide additional experimental evidence
that the intracellular domain is produced via proteolysis, we characterize the sheddase
involved, and we determine the regulated production and functions of the FGFR4
intracellular domain (R4-ICD).
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FGF19
There are 18 human FGF proteins that fall into 6 different subclasses. An
additional group of homologous factors, called FGF11-14, serve as nuclear factors and
are unable to activate any of the FGFRs [50]. The majority of receptor-dependent FGF
proteins signal through FGFRs in a paracrine or autocrine manner; however, one
subclass functions hormonally, sending soluble blood-borne signals throughout the
body. This is the FGF19 subclass and is made up of FGF19/15, FGF21 and FGF23.
These three proteins lack a heparan sulfate binding domain, allowing them to avoid
being limited to autocrine or paracrine signaling. As discussed previously, the FGF19
subclass utilizes cofactors alpha klotho (KLA) or beta klotho (KLB) as a cofactor or
coreceptor when signaling through FGFRs. FGF19 utilizes beta klotho.
FGF19 has known functions within the liver and the gallbladder. In the liver, it
negatively regulates bile acid synthesis by reducing CYP7A1 expression in hepatocytes,
reduces gluconeogenesis, and promotes protein and glycogen synthesis. FGF19 also
causes relaxation of the gallbladder muscle tissue [81].
In mice with genetic depletion of FGF15, the mouse FGF19 homolog,
administration of human FGF19 was able to effectively lower blood glucose in a
hyperglycemia model by promoting liver glycogen synthesis [81]. Transgenic mice
overexpressing FGF19 developed hepatocellular carcinoma by ten months of age,
showing an oncogenic effect beyond the metabolic effect. These mice showed
hepatocyte proliferation and differentiation prior to ten months [82]. Since hepatocytes
endogenously express FGFR4, and since FGF19 has a higher affinity for FGFR4 than
the other FGFRs, robust activation of this signaling axis within hepatocytes was
expected. While data show that FGFR4 expression correlates with a poorer prognosis in
cholangiocarcinoma patients [68], our data also suggest that normal human
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cholangiocytes lack expression of FGFR4. As such, an abundance of FGF19 is unlikely
to promote the development of cholangiocarcinoma in an otherwise healthy animal.
FGFR4 activation in hepatocytes leads to signaling through the Ras/Raf/MEK/ERK and
PI3K/AKT pathways [83]. Activating mutations in Ras are frequently seen as major
drivers in tumorigenesis and approximately 20% of all human tumors have activating
mutations in Ras genes [84]. As such, high dose FGF19 can functionally mimic an
activating mutation in Ras and lead to tumorigenesis in FGFR4-expressing cells.

Notch signaling
The Notch family is made up of four transmembrane glycoprotein receptors,
Notch1-4. This group of proteins is highly conserved across species. The
glycosyltransferases that modify Notch proteins, such as Lunatic Fringe and Protein OFucosyltransferase-1, have been tied to cancers. Lunatic Fringe, thought to be a tumor
suppressor, was shown to be deficient in basal-like breast cancer and prostate cancer
[85, 86]. Additionally, Protein O-Fucosyltransferase-1 (along with FGF19) gene
amplification has been observed in hepatocellular carcinoma, among other cancers [87,
88].
Functionally, Notch signaling can promote or suppress cell proliferation, cell
death, or differentiation and plays fundamental roles in developmental body patterning
as well as in adult tissue repair and regrowth. As such, abnormal Notch signaling
(increased or decreased) can lead to disease states including tetralogy of Fallot,
syndactyly, Alagille syndrome, and others [89, 90]. Alagille syndrome demonstrates the
relationship of Notch signaling to the biliary tree, where partial loss of Notch ligand
(Jagged-1) expression prevents the complete development of intrahepatic bile ducts.
Patients generally have a loss of one of the two Jagged-1 alleles (hemizygous), leading
to reduced Notch signaling. The portal vein endothelial cells normally express Jagged-1
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and signal to neighboring bipotential liver cells to induce differentiation into biliary
epithelial cells. When there is reduced Notch signaling, there is reduced intrahepatic bile
duct development and a congenital cholestatic disease can result. We note that Notch
signaling is also identified in malignant cholangiocarcinoma [91] and that hepatocytes
transduced with an oncogene plus Notch activation form cholangiocarcinomas [92].
Notch influences other cancers, too, where over 50% of T-cell acute
lymphoblastic leukemias have activating mutations in the Notch receptor. These
mutations are observed within the extracellular heterodimerization domain and/or the
intracellular PEST domain [93]. Structurally, Notch proteins are type 1 transmembrane
receptor hetero-oligomers, consisting of a large extracellular domain that contains
tandem EGF-like repeats (29-36) which participate in ligand binding [94]. Additionally,
they have a negative regulatory region that, as the name would suggest, autoinhibits
Notch activity in the absence of ligand, a single pass transmembrane region and an
intracellular portion. The Notch intracellular domain, NICD, contains an RBPJ-associated
module (RAM) domain, six ankyrin repeats (ANK, involved in protein interactions) and a
PEST domain that reduces Notch stability by promoting proteasomal degradation [95,
96]. Following Notch protein synthesis but prior to its integration into the plasma
membrane, the Notch receptor is cleaved at its S1 site while in the trans Golgi network.
This site is approximately 70 amino acids N-terminal from the transmembrane domain.
The two protein products from this cleavage event remain associated through calciumdependent ionic bonds. This ultimately results in a large entirely extracellular portion of
Notch bound to a smaller membrane-spanning portion (known as the TMF or
transmembrane fragment) [97]. Upon ligand binding the Notch receptor, the cell
expressing the transmembrane ligand on its plasma membrane attempts to endocytose
the ligand (and bound receptor). This traction force on the Notch receptor is
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hypothesized to cause conformational changes in the negative regulatory region, which
ultimately leads to deprotection and ADAM-mediated cleavage of the S2 site (on the
extracellular portion of the transmembrane fragment, 12 amino acids from the
membrane), leaving behind the Notch extracellular truncation (NEXT). Following S2
cleavage, endocytosis of ligand and a portion of the Notch receptor can occur on the cell
expressing ligand. S2 cleavage is the rate limiting step in Notch activation for the
receptor-expressing cell. At this point, γ-secretase accesses the S3 cleavage site
located in the intramembrane region near the outer leaflet of the plasma membrane on
NEXT. This is followed by a second γ-secretase-mediated cleavage, S4, which occurs
near the middle of the transmembrane region, resulting in release of the NICD [98].
NICD then mediates Notch signaling via its action in the nucleus [96, 97]. Once released
from the plasma membrane, the NICD interacts with DNA binding proteins in the CSL
family and regulates transcription of selected genes.
Notch canonical signaling in humans and mice occurs through activation by
ligands of the Delta like (DLL1, DLL3, DLL4) and Jagged (Jagged-1, Jagged-2) protein
families. Data suggest that signaling is dictated primarily by which receptor (Notch1-4) is
activated, and not which ligand is used to activate the receptor [96]. Notch cleavage and
signaling has also been shown to occur in a ligand-independent manner, utilizing CD28
and the T-cell receptor of nearby T-cells [99-101]. Data suggest that ADAM17 was the
protease necessary for ligand-independent S2 cleavage of Notch, whereas ADAM10
was the protease in ligand-induced S2 cleavage [102].
Notch proteins contain a large number of EGF repeats which can be Oglycosylated (O-fucose or O-glucose) to modify ligand-receptor signaling and allow for
subsequent receptor modification to occur. Fringe-family proteins are
glycosyltransferase enzymes involved in Notch modification that recognize O-fucose
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molecules. Fringe is able to add additional sugar moieties to the Notch receptor to
regulate ligand binding specificity. For example, the addition of a single N-acetyl
glucosamine molecule on EGF repeat 12 by Fringe can promote Notch binding and
activation by ligand, Delta, and reduce binding and receptor activation by an alternate
ligand, Serrate (a Jagged analog), in Drosophila. In mammals, multiple Fringe proteins
(Lunatic Fringe, LNFG; Manic Fringe, MNFG; and Radical Fringe, RNFG) add N-acetyl
glucosamine to EGF-like repeats 8 and 12 on Notch-1 [96, 103] and promote binding to
Delta-like ligand 1 (DLL1) [104-106]. LFNG- and MFNG-mediated glycosylation (addition
of N-acetyl glucosamine at EGF repeats 6 and 36) reduced Notch1-Jagged-1 signaling
[107].

Presenilin and γ-secretase
The Notch S3 and S4 cleavage events are both performed by γ-secretase, an
aspartyl protease that is made up of four subunits: nicastrin (Nct), anterior pharynx
defective 1 (APH-1), presenilin enhancer 2 (PEN2), and presenilin 1 or 2 (PSEN1 or 2).
Nicastrin, APH-1 and PEN2 promote proper maturation and assembly of γ-secretase
and allow the correct post-translational modifications to occur. PSEN1 or 2 is the
catalytically active subunit with aspartyl protease activity [108]. There is evidence to
suggest that PSEN can cleave single pass transmembrane proteins (within or outside of
the TM region), regardless of sequence, so long as the extracellular portion of the
protein is fewer than 200-300 amino acids in length. Additionally, there appears to be a
correlation between length of the ectodomain and efficiency with which γ-secretase
cleavage occurs; a protein with a larger ectodomain appeared to be cleaved less
efficiently than one with a smaller ectodomain [109]. As such, for proteins like Notch or
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β-APP, the initial ectodomain shedding event is necessary to shorten the extracellular
domain allowing for subsequent γ-secretase cleavage.
Merilahti and colleagues conducted a screening experiment to look for receptor
tyrosine kinases that could be proteolytically cleaved by γ-secretase [80]. In this screen,
45 human receptor tyrosine kinases were tested for their ability to undergo RIP via γsecretase in controlled conditions in transfected cells. They reasoned that activation of a
sheddase, combined with inhibition of γ-secretase, would lead to stabilization of a
partially cleaved intermediate, and detection of that intermediate was taken as evidence
that a receptor was a γ-secretase substrate. Phorbol 12-myristate13-acetate (PMA) was
used to activate Protein kinase C which in turn activates some sheddases. PMA is a
small molecule activator of Protein kinase C (PKC) with a structure similar to that of
diacylglycerol, an endogenous PKC activator. PKC promotes sheddase activity, leading
to RIP. Another tool used in their study was γ-secretase inhibitor IX (GSI IX, also known
as DAPT). GSI IX works through targeting the C-terminal domain (primarily
transmembrane domain seven) of presenilin [110]. Promotion of sheddase activity
(through PMA) and inhibition of γ-secretase activity (GSI IX), led to the accumulation of
membrane-anchored C-terminal fragments of RTKs that are normally cleaved by γsecretase. Nine RTKs that had previously been shown to undergo RIP were confirmed,
and 12 additional RTKs, including FGFR4, were newly shown to undergo RIP [80]. Their
data were only shown with tagged exogenous FGFR4 under the described experimental
conditions and they did not assess for a function of the proteolytic product. Thus, FGFR4
can undergo RIP, and our studies demonstrate the relevance of this processing in
signaling and in human tumors.
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Extracellular proteases
Most extracellular proteases fall into one of three main groups: metalloproteases
(MMPs, Adamalysins, and others), serine proteases, and cysteine proteases.
Extracellular proteases have been widely targeted pharmacologically due to their
important roles in both physiologic and pathologic processes. MMPs, or matrix
metalloproteinases, are a family of 24 human zinc-dependent endopeptidases able to
cleave and degrade extracellular matrix protein components [111-113]. Many MMPs are
soluble enzymes; however, MT-MMPs, or membrane-type MMPs are a group of six
membrane-associated matrix metalloproteases. Under physiologic conditions, they
contribute to tissue homeostasis and remodeling. In cancer, increased expression or
activation of MMPs can promote tumor cell growth, invasion and metastasis into
surrounding tissue, in addition to increasing angiogenesis [113]. Early MMP inhibitors
worked primarily through zinc chelation, which led to a lack of drug specificity, reducing
clinical applicability.
ADAM (a disintegrin and metalloproteinase) proteases are membrane-anchored
proteins whose catalytic domains share structural similarity with MMP catalytic domains.
As a result, ADAMs also require zinc for protease activity. Unlike MMPs, however,
ADAM proteins lack a hemopexin-like domain and have a cysteine-rich domain, EGFlike domain and a disintegrin domain (their namesake) [111]. Functionally, ADAMs
primarily regulate tumor cell adhesion and growth signaling [113]. Some MMPs,
including MMP7 and MMP14, can act as sheddases which proteolytically release the
extracellular portion of transmembrane proteins [114, 115]. Just over half of known
ADAM proteins (18/33) are predicted to have protease activity, with ADAMs 9, 10, 12
and 17 having demonstrated sheddase activity [113, 114]. These proteins play a crucial
role in initiating regulated intramembrane proteolysis by carrying out the initial cleavage
event.
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Proposed effects of glycosylation on FGFR4 signaling and processing
Thus far, several examples of proteolytic processing of integral membrane
proteins have been discussed, including various RTKs and Notch. In each of these
examples, an extracellular sheddase-mediated cleavage event is necessary for
subsequent proteolysis and release of the ICD. Receptor activation may be necessary
for this cleavage cascade to occur, as seen with FGFR3. In other cases (Notch, in
particular), glycosylation and other post-translational modifications are essential for
receptor function and affected signaling. In the case of Notch, O-linked glycosylation of
the EGF-like repeats was able to modify receptor ligand interactions. These specific
sites of glycosylation varied from species to species, but they were at least 300 amino
acids away from the TM region (Homo sapiens, Drosophila melanogaster), suggesting
that their major role was to modify receptor-ligand interactions.
In FGFR4, five extracellular N-linked glycosylation sites exist, with the most Cterminal site (Asn-322) located less than 50 amino acids from the transmembrane
region. The three most C-terminal sites (Asn-290, -311, and -322) fall within the IgIII
loop, and the two other sites (Asn-112, -258) are located between the IgI and IgII and
the IgII and IgIII loops, respectively. FGFR4 ligand binding occurs between the Nterminal portion of IgII and the C-terminal portion of IgIII. With this in mind, it would be
reasonable to hypothesize that glycosylation of FGFR4 could modify its ability to be
cleaved through altering receptor-ligand interactions and/or by directly altering the
interaction with sheddase(s) (Figure 2). In Chapter 3 of this dissertation, I show that the
cleavage product of FGFR4, R4-ICD, was increased by removing N-linked glycans from
the ectodomains of cell surface proteins or by reducing a cell’s intrinsic ability to
glycosylate proteins at Asn residues. This led to our subsequent experiments to further
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test the role of glycosylation in regulating FGFR4 cleavage, where we employed sitedirected mutagenesis to prevent glycosylation of the predicted five Asn that could be
modified. Each of these Asn residues was individually mutated to a glutamine residue
and expressed as a single mutant. In addition, a combined 4Q mutant, in which 4 of the
5 asparagine residues were mutated to glutamine, was generated.
In addition to looking at the effects of glycosylation on FGFR4 signaling and
processing, I investigated how FGFR4 proteolysis to R4-ICD occurs. In
cholangiocarcinoma cells, inhibiting FGFR4 signaling has been shown to reduce cell

FGF19
Asn-112

Asn-290

Asn-258

S1: sheddase

Asn-311

TM

Asn-322

P

802

Figure 2. Schematic of FGFR4 with possible sheddase cleave site.
Structurally, FGFR4 contains three extracellular immunglobulin-like loops, and five
asparagine (Asn) residues capable of undergoing N-linked glycosylation. FGF19, a
ligand for FGFR4, has been shown to bind at the receptor between
immunoglobulin-like loops two and three. Here, the ligand binding site and putative
S1 cleavage area are highlighted and the proximity of these two areas to N-linked
glycosylation sites is emphasized.
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proliferation and increase cell susceptibility to apoptosis. As such, inhibiting FGFR4 may
be a reasonable approach to treating patients with FGFR4-positive cholangiocarcinoma.
Initial screening experiments by others have shown that FGFR4 can be proteolytically
processed by γ-secretase, but γ-secretase activity typically requires that the substrate
has undergone an initial shedding event. Further, those studies did not functionally
characterize the R4-ICD.
We reasoned that in the absence of the extracellular domain, R4-ICD would be
freed from the inhibitory effect of the receptor and freed from reliance on ligand, thus
having constitutive activity. Experiments in this dissertation demonstrated that R4-ICD is
the predominant form of FGFR4 observed in human cholangiocarcinoma tissue samples
and glycosylation regulates R4-ICD production. Importantly, glycosylation of FGFR4
itself decreased proteolytic processing, contrary to the effects of non-selective
deglycosylation that increased proteolytic processing of FGFR4, suggesting that
glycosylation of other cellular factor(s) regulates R4-ICD production (Chapter 3). Further,
ADAM10 acted as the sheddase necessary for FGFR4 processing to R4-ICD and
PSEN2 contributed to R4-ICD production as well. In addition, inhibition of the FGFR4
kinase reduced processing of FGFR4. Finally, we demonstrated that R4-ICD, in the
absence of full-length FGFR4, could activate tumor cell signaling.
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CHAPTER 2: METHODS
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Cell culture:
Human malignant cholangiocarcinoma cells, KMCH and HuCCT1, were kindly
provided by Dr. Gregory Gores. Cells were cultured in high-glucose DMEM
supplemented with 10% fetal bovine serum (FBS), G418 (50 μg/mL), and insulin (0.5
μg/mL). FGFR4 plasmids were generously provided by Dr. Javed Khan (National Cancer
Institute) and have been described previously [74]. HuCCT1 cells were transfected and
selected with puromycin (2-10 µg/mL). Single-cell colonies were isolated.

Immunoblotting:
Cells were lysed by the addition of 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA,
1 mM dithiothreitol, 1 mM α-phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 100 mM NaF,
and 1% Triton X-100, pH 7.4. Following SDS-PAGE and transfer to nitrocellulose
membrane, FGFR4 signal was detected via immunoblotting: FGFR4 monoclonal rabbit
(Cell Signaling Technology: #8562) or Actin monoclonal mouse (Sigma Aldrich: A2228).
Antibody specificity was verified via the molecular weight of FGFR4, a decrease in signal
upon use of an shRNA against FGFR4 (see chapter 4), and restored signal with
transfection of an FGFR4 expression plasmid.

Post-translational modifications:
Glycosylation was altered by enzyme-mediated deglycosylation, inhibition of
glycosyltransferase, or site-directed mutagenesis. PNGase F and Endoglycosidase H
were from New England Biolabs (PNGase F: P0704S, Endoglycosidase H: P0702S).
NGI-1 (Selleckchem: S8750) was added to cells at 0-100 μM, overnight. Kifunensine
(Cayman Chemical: 10009437), 5 μM, was added to cells for 0-16 hours.
Enzyme-mediated deglycosylation, lysate: Cells were lysed in the manufacturersupplied lysis buffer at a final concentration of 1% NP-40. Lysates were vortexed briefly
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three times and placed on ice between each. Lysates were centrifuged (13,000g, 5 min)
and the supernatant saved. The supernatant (5 µL) was incubated under native or
denaturing conditions (denaturing buffer, 100°C incubation), per the manufacturer and
the reaction started by addition of 500 units of enzyme. The reaction was terminated with
one volume of 2X Laemmli buffer, and the samples were heated to 95°C for 5 min.
Enzyme-mediated deglycosylation, live cells: Cells were plated at 70-80%
confluency in a 12-well plate. Medium was replaced with Opti-MEM medium
(ThermoFisher Scientific: 22600050) containing 5,000 units of PNGase F per mL for 1-4
hours. Protein isolation was performed on ice to prepare samples for immunoblotting, as
above.
Phosphatase: The manufacturer’s protocol was used (New England Biolabs,
Lambda Protein Phosphatase: P0753S), with modification. Protein isolation and
denaturation steps were identical to those performed in the PNGase F denatured lysate
protocol. Following deglycosylation, 2 μL of protein metallophosphatase (PMP) buffer
(50 mM HEPES, 100 mM NaCl, 2 mM DTT, 0.01% Brij 35, pH 7.5), 2 μL of 10 mM
MnCl2 and 6 μL of water were added to the 10 μL sample to give a total reaction volume
of 20 μL.

Site-directed mutagenesis:
Agilent QuikChange Lightning, 210519, or New England Biolabs Q5 SiteDirected Mutagenesis, E0554, were used to replace each of the five predicted
glycosylation residues (Asn-112, -258, -290, -311, -322) to convert asparagine to
glutamine. All mutations were confirmed through sequencing.
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Site-directed mutagenesis (in depth):
NEB (E0554S): primer sets were of various lengths (10-20 NTs), and the six
most 3’ NTs had only one site of binding in the plasmid sequence to reduce off-target
binding. Forward and reverse primers were designed to be directly adjacent, but nonoverlapping, with the mutation incorporated into only one of them (near the 5’ end of the
forward primer). Prior to ordering, primers were checked for self-annealing sites, hairpin
loops, or complementarity [116]. Annealing was typically performed at 60°C. This
method was successfully used to mutate sites N112 and N258.

Agilent (210519): primers were designed, in part, using Agilent’s online program.
Sequences were entered in, and specific mutation(s) were selected. Agilent then
provided a set of completely overlapping complementary primer pairs which both
contained the mutation(s). The seven most 3’ NTs had only one site of binding in the
plasmid sequence to reduce off-target binding. Prior to ordering, primers were checked
for self-annealing sites, hairpin loops, or complementarity [116]. An annealing
temperature of 60°C was used with a general elongation rule of 30 seconds/kb. The
Agilent protocol was followed precisely, aside from using SOC broth instead of NZY+
broth. This method was successfully used to mutate sites N290, N311, and N322.

Active lysate isolation:
We measured receptor cleavage of FGFR4 full-length protein to R4-ICD, in the
absence of protein synthesis and glycosylation, in crude lysate, based on reports using
crude cell lysate to measure endogenous enzyme activity [117, 118]. Cells were
mechanically lysed in hypotonic non-denaturing lysis buffer (30 mM NaCl, 20 mM Tris,
pH 7.4), either by Dounce homogenization (larger volumes) or needle shearing (small
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samples). Initial experiments on the same sample demonstrated no difference between
these methods. Dounce homogenization (glass/ground glass) was done with 20 passes
per sample and needle shearing with 20 passes through a 29-gauge needle. Lysates
were either frozen immediately or incubated at 37°C. Processing was arrested by adding
Laemmli buffer and heating to 95°C for 5-minutes.

Protein isolation from frozen tissue:
This process can be time sensitive. As such, all necessary supplies were
gathered and select supplies were cooled with liquid nitrogen before removing samples
from the -80°C freezer. In the fume hood, gather the following supplies: weigh boats,
lysis buffer (the same buffer used for normal protein isolation), pipette/tips,
syringe/needle, mortar and pestle, sharps container, liquid nitrogen, gloves, formalin
cups with cassettes and Eppendorf tubes.
Liquid nitrogen was poured into the mortar to cool it down. Once cooled,
additional liquid nitrogen was added to the mortar along with the tissue sample. Liquid
nitrogen was added as needed to keep tissue frozen. Covering the mortar with one hand
and holding the pestle in the other, the tissue was crushed with a single blow. This
served to break the tissue into several pieces, so that a portion could be saved for RNA
isolation, frozen back down, or placed into the tissue cassette (and formalin) for
sectioning and slide creation.
The portion remaining in the mortar was used for protein isolation and was
crushed into a fine powder, while maintaining cold temperature. Liquid nitrogen (swirling)
was used to collect the powder back to the bottom of the mortar. Highly desmoplastic
tissue is very challenging to grind. The ground up tissue was collected into a weigh boat
containing lysis buffer and passed through a syringe and needle until the solution was
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homogenized. The homogenate was then transferred to a 1.5 mL tube, and protein (or
RNA) isolation was performed using the protocol described above.

Migration:
Cells were plated into transwell inserts at 5,000 cells/well in serum-free medium
(Sigma, CLS3422-48EA). Medium in the lower chamber contained 10% fetal bovine
serum (FBS). At 24 hours, non-migrated cells were removed and the insert processed
[119]. Cells from five non-overlapping images (field of view was 1 mm x 1.4 mm) per
insert were counted using CellProfiler (CellProfiler pipeline has been included below).
CellProfiler pipeline used:
Pipeline name
Metadata
NamesAndTypes

Groups
IdentifyPrimaryObjects

Setting items
Extract meta data? No
Asign a name to: All images
Process in 3D? No
Select the image type: Grayscale image
Name to assign these images: Nuclei
Set intensity range from: Manual
Maximum intensity: 255
Do you want to group your images? No
Use advanced settings? Yes
Select the input image: Nuclei
Primary objects to be identified: Nuclei
Typical diameter of objects, in pixel units (Min, Max): 3, 9
Discard objects outside the diameter range? Yes
Discard objects touching the border of the image? Yes
Threshold strategy: Adaptive
Thresholding method: Otsu
Two-class of three-class thresholding? Three classes
Assign pixels in the middle intensity class to the
foreground or the background? Foreground
Threshold smoothing scale: 1.3488
Threshold correction factor: 1
Lower and upper bounds on threshold: 0, 1
Size of adaptive window: 10
Method to distinguish clumped objects: Shape
Method to draw dividing lines between clumped objects:
Shape
Automatically calculate size of smoothing filter for
declumping? Yes
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Automatically calculate minimum allowed distance
between local maxima? Yes
Speed up by using lower-resolution image to find local
maxima? Yes
Display accepted local maxima? No
Full hole in identified objects? After declumping only
Handling of objects if excessive number of objects
identified: Continue
MeasureObjectSizeShape Select object sets to measure: Nuclei
Calculate the Zernike features? No
Calculate the advanced features? No
MeasureObjectIntensity
Select images to measure: Nuclei

Caspase activity:
Caspase 3/7 activity was measured by quantifying the release of Rhodamine-110
from the peptide DEVD (Promega: G7792) according to the manufacturer’s instructions,
with quadruplicates of each group. Cells were treated as described in the figure legends.
The following day, apoptosis was stimulated with 10 ng/mL TNF-related apoptosisinducing ligand (R&D Systems, 375-TL-010) for 6 hours. Alternatively, apoptosis was
stimulated with Cisplatin (Fresenius Kabi: 63323-103-51) and gemcitabine (Zydus
Hospira Oncology: 0409-0185-01) at 50 and 5 µM respectively, or staurosporine (Fisher
Scientific: BP2541-100) at 2 ng/mL for 24 hours.

FGFR4 localization:
Cells plated on collagen-coated coverslips were fixed in 3% paraformaldehyde in
dPBS with 100 mM PIPES, 3 mM MgSO4 & 1 mM EGTA then permeabilized in 0.1%
Triton X-100 in dPBS. Primary antibodies (Protein-Tech anti-FGFR4: 11098-1-AP or
Abcam anti-Giantin: ab37266) were used at 1:50. Secondary antibody (Thermo Fisher,
donkey anti-rabbit, 594 nm: A21207, donkey anti-mouse, 488 nm: A21202) was added
(1:2,000, FGFR4 or 1:200, Giantin) for 45 minutes at room temperature. Samples were
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mounted in ProLong Gold with DAPI. A Zeiss LSM 800 with Airyscan was used for
confocal imaging.
Differential centrifugation
A differential-fractionation protocol modified from Bitler, et al., 2010 and Ramsby
et al., 1994 was performed and is described below [120, 121]. Cells at confluency were
washed with 1X PBS, trypsinized and pelleted through centrifugation (200 x g for two
minutes). The supernatant was discarded, and the pellet was resuspended in 200 μL of
digitonin lysis buffer (0.01% digitonin, 100 mM NaCl, 300 mM sucrose, 10 mM PIPES
(pH 6.8), 3 mM MgCl2, 5 mM EDTA, 2 mM Na3VO4, 50 μM ammonium molybdate, 10
mM NaF and complete protease inhibitors (Roche) and incubated on ice for five minutes.
Sample was then centrifuged for 10 minutes at 400 x g. The supernatant (cytosolic
fraction) was collected and saved. The pellet was resuspended in 200 μL Triton X-100
lysis buffer (0.5% Triton X-100, 100 mM NaCl, 300 mM sucrose, 10 mM PIPES (pH 7.4),
3 mM MgCl2, 3 mM EDTA, 2 mM Na3VO4, 50 μM ammonium molybdate, 10 mM NaF
and complete protease inhibitors (Roche)) and incubated on ice for five minutes. Sample
was then centrifuged at 5,000 x g for 10 minutes, and the supernatant was collected as
the membrane fraction. The remaining pellet was resuspended in 300 μL Tween
20/DOC lysis buffer (1% Tween 20, 10 mMNaCl, 0.5% deoxycholate, 10 mM PIPES (pH
7.4), 1 mM MgCl2, 2 mM Na3VO4, 50 μM ammonium molybdate, 10 mM NaF and
complete protease inhibitor (Roche)). Pellet homogenization was performed 20 times
using a dounce homogenizer followed by ten cycles of sonication (30 seconds on,
followed by 30 seconds off. The sample was then centrifuged for 10 minutes at 7,000 x
g, and the supernatant was collected as the nuclear fraction.
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Protease inhibition screening
Active cell lysates were collected via Dounce homogenization. Inhibitors were
individually added to the lysate or the lysate was subjected to heat denaturation at 95°C
for 1 or 5 minutes. A list of inhibitors used, the concentration at which they were used
and their known molecular targets is provided below:
GW280264x

2 μM

ADAM10 and
ADAM17

GI254023x

2 μM

ADAM10

Ilomastat

20 μM

multiple MMPs

Ortho-

100 μM

multiple MMPs

10 μM

granzyme B

phenanthroline
Granzyme B
inhibitor
Lysates were then incubated for an hour at 37°C. Processing was arrested by adding
Laemmli buffer and heating to 95°C for 5-minutes.

RNA isolation
The following steps were performed in a chemical fume hood to minimize
exposure to harmful chemicals. Medium was removed from each well of a six-well plate.
To each well, 500 μL of Trizol reagent was added. Cell homogenization was performed
by pipetting the Trizol reagent up and down several times. The Plates with Trizol reagent
were incubated for 5 minutes at room temperature and the homogenates were then
collected in microcentrifuge tubes. To each tube, 100 μL of chloroform was added.
Tubes were then vortexed for 15-30 seconds and then incubated for 15-20 minutes at
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room temperature. Samples were centrifuged for 15 minutes at 12,000 x G, 4°C. This
separated samples into an RNA phase layer (top, clear) and an organic layer (bottom,
red). Being very careful not to remove any of the phenol, the top clear layer was
removed and placed into clean microfuge tubes. To the clear layer, 250 μL of
isopropanol was added, and the samples were gently mixed by inversion. Samples were
incubated at room temperature for 10 minutes and then centrifuged for 10 minutes at
12,000 x G, 4°C. The supernatant was removed without disrupting the RNA pellet. The
pellet was then washed with 1 mL of 70% ethanol and centrifuged again for 5 minutes at
7,500 x G, 4°C. Ethanol was carefully removed and the pellet was allowed to air dry for
5-10 minutes. The pellet was resuspended in 100 μL of DEPC-containing water and
incubated at 55°C for 10 minutes. Samples were then immediately quantified and stored
at -80°C to prevent degradation.

Knockdown using siRNA
HuCCT-FGFR4 cells were grown to ~60% confluency in a six-well plate. A
modified RNAiMAX protocol optimized for our cells was used. Negative control or siRNA
was added to 250 μL of OptiMEM medium at a concentration 200 nM. In a separate
tube, 5 μL of RNAiMAX solution was added to 250 μL of OptiMEM medium. The two
mixtures were combined and allowed to sit at room temperature for ~15 minutes. The full
volume (~500 μL) was then added to one well of a six-well plate. Cells were incubated
with negative control or siRNA for 36-72 hours at 37°C in CO2-controlled incubator. Once
cells reached confluency, protein or RNA isolation was performed using standard
protocols.
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Reverse transcription polymerase chain reaction (cDNA synthesis)
Two μg of RNA were added to a solution containing 10 μM random hexamers
and 1 mM dNTPs. The samples were heated at 65°C for 5 minutes and then cooled on
ice. To each sample volume, an equal volume of the following solution was added: 2x
first strand buffer, 25 mM DTT, 2 unit/μL RNase inhibitor (ThermoFisher: N8080119), 20
units/μL M-MuLV reverse transcriptase (New England Biolabs: M0253S). This reaction
was allowed to incubate for 20 minutes at 42°C followed by 10 minutes at 95°C.

Quantitative polymerase chain reaction
SYBR green reagent was used for detection. In a 20 μL reaction volume, 10 μL
of SYBR green, 6 μL of DEPC H2O, Primer mix (final concentration of 0.5 μM) and 3 μL
of cDNA were mixed together in a 96 well plate. Optimization of primer and cDNA
concentrations were performed prior to starting the experiment.
The thermocycler was run using the following setup:
1. Activation: 95°C for 2 minutes
2. Denaturation: 95°C for 5 seconds
3. Annealing/extension: 60°C for 30 seconds
a. Steps 2 and 3 repeated 40 times
4. Melt curve: 65-95°C with 0.5°C increments, 5 seconds/increment

Enrichment for FGFR4
Cell lysate was collected using Pierce lysis buffer (25 mM Tris HCl pH 7.4, 150
mM NaCl, 1% NP-40, 1 mM EDTA, 5% glycerol). Cells were scraped off the plate into
buffer and vortexed three times with a five-minute incubation on ice between each
vortex. Between 120 and 200 μg of protein was aliquoted into each tube. Primary
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antibody (FGFR4: Thermofisher MA5-18084, p-ELK-1: Cell Signaling 9186S), 1:100
(v/v), was added to each aliquot and was allowed to incubate with rotation at 4°C for an
hour. Protein G magnetic beads were then added to each sample at a 1:5 dilution.
Samples were then incubated with rotation at 4°C for one hour. Magnetic separation of
the beads was performed, and the remaining solution was discarded. Beads were
washed six times with 30 mM NaCl, 20 mM Tris, pH 7.4. Beads were then resuspended
in 2 μM ZnCl2, and human recombinant ADAM10 (R&D systems 936-AD) was added at
a final concentration of 22 ng/μL, 44 ng/μL or 66 ng/μL. Samples were incubated for one
hour at 37°C. The reaction was terminated and protein was eluted from the beads by the
addition of 5x Laemmli buffer followed by a five-minute incubation at 70°C. Beads were
removed (magnetically) and samples were saved and analyzed via immunoblot.
Recombinant human ADAM10 activity and active cell lysate activity were tested
using a peptide substrate containing a fluorophore on one end and quenching molecule
on the other end (R&D systems: ES010). Stock solution of substrate 10 mg/mL in
DMSO, and substrate is used at a final concentration of 0.22 g/mL. Excitation
wavelength used was 320 nm, and absorption wavelength measured was 405 nm.

Transient transfection of mammalian cells:
Cells at 70-90% confluency in a well of a 6-well plate were used for transfection.
Lipofectamine 3000 reagent, 3.75 μL was added to 125 μL of Opti-MEM medium. In a
separate tube, 5 μg of uncut plasmid DNA and 10 μL of P3000 reagent were added to
125 μL of Opti-MEM media. Their contents were combined and incubated for 10-15
minutes at room temperature. The total volume (~250 μL) was added to one well of a 6
well plate, and the cells were allowed to incubate and grow for 2-4 days at 37°C.
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Stable transfection of mammalian cells:
This protocol is nearly identical to the transient transfection protocol, except that
linearized plasmid DNA was used in the transfection process. The linearization protocol
was as follows:
1x BSA, 1x buffer (appropriate for restriction enzyme), restriction enzyme, plasmid
(variable amount), water to volume were added to a PCR tube. Samples were digested
for 1 hour at required temperature. To stop the reaction, samples were heated to the
specified “kill” temperature for the required duration. The transfection was then
continued as normal.

Production of clonal cell lines:
Transfected cells were allowed to grow in regular medium for 24 hours. At this
point, the medium was removed and puromycin-containing (3 μg/mL) medium was
added to the cells. Medium was changed every 2-4 days, more often if necessary, to
remove dead cells. This was done until >80% of the cells had been removed. At this
point, medium change occurred infrequently, as needed. The cell population in the dish
was very low, and single cells were allowed to grow in selection medium. Once a
majority of single cell colonies had proliferated into colonies of 200+ cells, colonies were
isolated/picked. Medium was removed and trypsin was briefly added to the plate. Using
the inverted microscope for colony visualization, the P10 pipette (with 10 μL of medium
in the tip) was slowly and carefully scraped across a single colony, using the medium in
the tip to pull up cells. Cells were then transferred to a single well of a 24 well plate. This
process was repeated until most/all of the colonies had been picked. Cells in each well
in the 24 well plate were allowed to grow to near confluency before being expanded to
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two wells of a 12 well plate (one well for protein isolation and screening, one well for
maintenance).
HuCCT R4-ICD PB1 cells were produced through stable transfection of HuCCT
cells with pCDNA 3.1 containing cDNA coding for FGFR4 residues 391-802 with a Cterminal HA tag. No selection gene was present in the plasmid, so colonies were grown
and individually screened for expression of R4-ICD by immunoblot.
HuCCT R4-ICD C3 and C6 cells were produced through stable transfection of
HuCCT cells with pBABEzeo containing cDNA coding for FGFR4 residues 391-802. This
plasmid contains a zeocin-resistance gene. As such, cells were grown in medium
containing zeocin, 800 μg/mL. Clonal growth, colony selection and screening via
immunoblot followed.

Statistical analysis:
For quantitative comparisons between two conditions, the Student’s t-test was
used. When comparing more than two conditions, ANOVA test with post-hoc correction
(Bonferroni) was used.
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CHAPTER 3: Glycosylation of FGFR4 in cholangiocarcinoma
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Abstract
Recent advances in targeted treatment for cholangiocarcinoma have focused on
fibroblast growth factor (FGF) signaling. There are four receptor tyrosine kinases that
respond to FGFs, and posttranslational processing has been demonstrated for each
FGF receptor. Here, we investigated the role of N-linked glycosylation on processing and
function of FGFR4. We altered glycosylation through enzymatic deglycosylation, small
molecule inhibition of glycosyltransferases, or through site-directed mutagenesis of
selected asparagine residues in FGFR4. Signaling was tested through caspase
activation, migration, and subcellular localization of FGFR4. Our data demonstrate that
FGFR4 has multiple glycoforms, with predominant bands relating to the full-length
receptor that has a high-mannose and hybrid-type glycan form and a complex-type or
mature glycan form. We further identified a set of faster migrating FGFR4 bands that
correspond to the intracellular kinase domain, termed R4-ICD. These glycoforms and
R4-ICD were detected in human cholangiocarcinoma tumor samples, where R4-ICD was
predominant. Removal of glycans in intact cells by enzymatic deglycosylation resulted in
increased processing to R4-ICD. Inhibition of glycosylation using NGI-1, an
oligosaccharyltransferase inhibitor, reduced glycosylation of FGFR4, increased
processing, and sensitized cells to apoptosis. Mutation of Asn-112, Asn-258, Asn-290, or
Asn-311 to glutamine modestly reduced apoptosis resistance, while mutation of Asn-322
or simultaneous mutation of the other four asparagine residues caused a loss of FGFR4dependent cytoprotection. None of the glycomutants altered the migration of cancer
cells. Finally, mutation of Asn-112 caused a partial localization of FGFR4 to the Golgi.
Overall, preventing glycosylation at individual residues reduced the cell survival function
of FGFR4 and receptor glycosylation may regulate access to an extracellular protease or
proteolytic susceptibility of FGFR4.
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Introduction
Cholangiocarcinoma is a primary liver cancer of the epithelial cells lining the biliary
tract. Cholangiocarcinoma commonly presents late in disease and patients have a very
poor prognosis; less than 10% 5-year survival [1]. Treatment options include newly
approved small molecule inhibitors targeting FGFRs, IDH1, and ROS1 [122, 123].
However, many of these treatment options are only approved for a select group of
patients. As such, gemcitabine plus cisplatin remains a common first-line therapy [6]. In
the meantime, finding new therapeutic targets in cholangiocarcinoma remains a top
priority.
One such group of therapeutic targets includes receptor tyrosine kinases (RTK),
such as fibroblast growth factor receptors (FGFR). FGFR4 signaling has a role in healthy
liver function through regulation of bile acid synthesis. In cancer biology, FGFR4 has
been shown to play a role in malignant signaling through its overexpression. This has
been observed in various tumors including breast, lung, gastric cancers,
rhabdomyosarcoma, nasopharyngeal carcinoma, and cholangiocarcinoma [67, 68, 71,
74].
There are five FGFRs (only four with functional kinase domains) and twenty-three
FGF ligands [37]. FGF19 is expressed in biliary tissue and is amplified in 4-6% of
cholangiocarcinomas [77, 124-126]. FGF19’s receptor, FGFR4, is also expressed in
cholangiocarcinoma. Ligand binding occurs between the second and third
immunoglobulin loop structures. In the presence of the coreceptor, beta klotho (KLB),
receptor dimerization can occur and autophosphorylation of the FGFR kinase domain
follows [127, 128]. N-linked glycosylation of FGFR4 plays a role in FGFR4 localization
and signaling [61, 62].
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Some similarities exist between Notch and the FGFR family protein, FGFR3.
Dysregulation of Notch signaling has been implicated in cancer. Notch3 overexpression
was observed in approximately 40% of non-small cell lung cancers (NSCLC). Often, this
was observed with reduced manic fringe expression. Manic fringe is one of the three
human glycosyltransferases that modify Notch proteins [103, 129]. When manic fringe
expression was restored, Notch3 was destabilized, and tumor growth was reduced [130].
FGFR3 has been shown to undergo regulated intramembrane proteolysis. After ligand
binds to the extracellular portion of FGFR3 and the kinase domain is phosphorylated, S1
cleavage occurs, releasing the extracellular domain. The membrane-anchored remaining
portion of FGFR3 undergoes a second cleavage event, S2, which effectively releases
the intracellular domain from the plasma membrane, allowing nuclear translocation. As is
observed in Notch signaling, FGFR3 activation (receptor phosphorylation) is required for
proteolysis to occur [22]. FGFR4 has five extracellular asparagine residues which match
the Asn-X-Ser/Thr sequon (where X is any amino acid except proline) required for Nlinked glycosylation to occur. These asparagine residues are located at positions 112,
258, 290, 311, and 322. The current study investigated the functional role of FGFR4
glycosylation in cholangiocarcinoma and the effects of glycosylation on processing to
R4-ICD.

Results

FGFR4 glycosylation in cholangiocarcinoma
N-linked glycosylation is predicted to occur at five residues in FGFR4 (Figure 3A).
Cholangiocarcinoma cell lines, HuCCT1-FGFR4 and KMCH, demonstrated two
predominant full length FGFR4 forms running at roughly 90 and 110 kDa on

B.
Asn-112
Asn-258

Asn-290
Asn-311
TM

Asn-322

KMCH

A.

HuCCT1
HuCCT1-FGFR4
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Figure 3. FGFR4 glycosylation in cholangiocarcinoma.
A. Schematic of FGFR4 showing three Ig-like loops, five predicted N-linked
glycosylation sites, the transmembrane (TM) domain and the intracellular C-terminal
kinase domain. B. HuCCT1, HuCCT1-FGFR4, and KMCH cells were immunoblotted
for FGFR4. Full-length receptor is visualized at 90-110 kDa and R4-ICD is observed
as signal around 45-50 kDa; representative of n=3. C. FGFR4/R4-ICD protein
expression in three healthy (donor) liver samples, three non-tumor samples adjacent
to liver cancer (Adj to tumor), and fourteen human cholangiocarcinoma tumor
samples.
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immunoblots, plus signals at 45-50 kDa, consistent with the predicted size of the
intracellular domain (amino acids 391-802). The faster migrating forms (45-50 kDa) were
collectively termed R4-intracellular domain (R4-ICD) based on size and immunoreactivity
to the C-terminal anti-FGFR4 antibody. R4-ICD was absent in cells lacking full-length
FGFR4 (HuCCT1 parental) and was present in cells transfected with FGFR4 (HuCCT1FGFR4; Figure 3B). Because we observed R4-ICD in HuCCT1 cells transfected with
cDNA for FGFR4, and cDNA is not a substrate for splicing, we reasoned that R4-ICD is
not an alternative splice variant. Similar 45-50 kDa forms of FGFR4 have been reported,
although their function has not been studied [60, 80]. In summary, FGFR4 protein
showed multiple forms with the 90-110 kDa forms potentially representing glycosylated
receptor and the faster migrating R4-ICD forms likely representing proteolytically
processed FGFR4. The level of R4-ICD signal relative to full-length showed variability,
suggestive of regulation.

FGFR4 in human liver tissue and cholangiocarcinoma
FGFR4 in human cholangiocarcinoma was investigated from archived, frozen
tumor samples. Samples were from 3 normal livers adjacent to tumor, 3 non-tumor
livers, and 14 tumors, including 6 male and 8 female patients. One cancer patient was
32 years old, the rest were in the range of 50-72 years, with an average age of 60
(Table 1). R4-ICD signal was stronger than full-length FGFR4 in human samples and
R4-ICD was observed in all 14 of the tumor samples. The lighter exposure blot
demonstrated substantially higher levels of R4-ICD in tumor samples compared to nontumor. Robust signal from full-length FGFR4 was observed in 12 of 14 tumor samples,
but only 3 out of 6 normal tissues. Note that one tumor-adjacent sample (lane 4) was
likely poorly preserved and exhibited a strong signal without distinct banding for FGFR4
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Lane Tumor

Age Sex Anatomic Notes
site

7

T6#

72

F

liver

8

T5*

64

M

liver

9

T1

59

F

liver

intrahepatic

10

T2

55

M

liver

intrahepatic

11

T3

52

F

liver

12

T4

50

F

liver

13

T7

63

F

14

T8

66

15

T9

50

16

T10

17
18

Histologic grade
(differentiated)

intrahepatic

AJCC stage
pT2a, pN0, pMX

moderately

pT3, pN0, pMX

moderately to
poorly
well

T2, N0, MX

moderately

pT1, NX, MX

moderately

T3, N0, MX

liver

multiple tumors
within the hepatic
parenchyma
intrahepatic

M

liver

intrahepatic

poorly

pT1, NX, MX

M

gallbladder gallbladder (met)

moderately

pT3, pN1

32

M

liver

moderately

pT2a, pN0, pMX

T11

65

F

pancreas

pancreas (met)

moderately

pT3, pN1

T12

69

M

liver

intrahepatic

well

pT1a, NX, MX

19

T13

72

F

liver

intrahepatic

poorly

pT2, NX, MX

20

T14

72

F

liver

Intrahepatic

moderately

pT2, pN0, pMX

1

Normal
donor
liver
ND1

liver

transplant (donor)

2

ND2

liver

transplant (donor)

3

ND3

liver

transplant (donor)

Anatomic
site

4

Adjacent
normal
tissue
N1

liver

adjacent to HCC

5

N2#

liver

6

N3*

liver

adjacent to
cholangiocarcinoma
adjacent to
cholangiocarcinoma

pT2, pN0, pMX

Table 1.
Patient characteristics for 14 tumor samples and 6 non-tumor livers were utilized
in this study. *Indicates that tumor T5 and liver sample N3 were from different
regions of the same liver. # Indicates that tumor T6 and liver sample N2 were from
different regions of the same liver.
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and very weak actin levels. Overall, tumor samples showed high levels of FGFR4 and
R4-ICD (Figure 3C).
FGFR4 glycosylation was examined by treatment with Endoglycosidase H to
remove high-mannose and hybrid-type glycans. Endoglycosidase H caused a shift of the
90 kDa band to two faster migrating bands at approximately 80-85 kDa. The 90 kDa
band was fully susceptible to Endoglycosidase H processing, indicating that this band
represents the high-mannose and hybrid-type glycan form of FGFR4 while the 110 kDa
band was not susceptible. Both denatured and native preparations were similarly
susceptible to Endoglycosidase H (Figure 4A).
PNGase F cleaves glycans between the innermost N-acetylglucosamine and the
protein, removing both high-mannose and complex-type glycans. Treatment of cell
lysates with PNGase F altered the migration of both the 90 kDa and 110 kDa FGFR4
bands, providing further evidence that they represent FGFR4 glycoforms (Figure 4B).
Collectively, these data confirm that FGFR4 is N-glycosylated, identify the 90 kDa band
as the immature high-mannose/hybrid-type glycan form, and identify the 110 kDa band
as the terminally-modified complex-type glycan form. We speculate that the doublet
seen after deglycosylase treatment represents a non-glycan posttranslational
modification to FGFR4. To determine whether the FGFR4 or R4-ICD bands observed
following enzymatic deglycosylation represented different phosphorylation states of
FGFR4, lysates were treated with lambda phosphatase. No obvious shifts of 80-110 kDa
forms were seen, suggesting that phosphorylation of full length FGFR4 does not play a
major role in FGFR4 migration. However, no positive control was included in this
experiment. R4-ICD was largely converted to the faster of 2-3 forms at 45-50 kDa upon
phosphatase treatment. Shifting seen for R4-ICD indicates the multiple bands of R4-ICD
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Figure 4. FGFR4 deglycosylation increased R4-ICD production.
A. Endoglycosidase H treatment of HuCCT1-FGFR4 cell lysates. The band labeled
“Deglyc” represents the deglycosylated form of FGFR4, and the band labeled
“Hybrid/Hi man” represents the hybrid or high mannose form of FGFR4. B. PNGase
F treatment of HuCCT1-FGFR4 cell lysate. C. Treatment of HuCCT1-FGFR4 cell
lysates with both PNGase F and Lambda phosphatase. Each experiment was
performed one time.
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may represent different phosphorylation states of the protein (Figure 4C). The stability of
the different phospho-forms of R4-ICD was not determined.
Next, live cells in culture were incubated with PNGase F in the media to
enzymatically deglycosylate FGFR4 at the cell surface. Western blot analysis
demonstrated that complex glycosylated FGFR4 (110 kDa) shifted to an 85 kDa band,
similar to deglycosylated FGFR4, while the hybrid/high mannose 90 kDa form persisted
(Figure 5A). PNGase F enzyme is presumably excluded from the cell interior, thus
deglycosylation is restricted to FGFR4 that is present on the cell surface, presumably
explaining the difference in the migration compared to Figure 2B. PNGase F digestion
for 1-2 hours resulted in increased R4-ICD signal, especially at ~50 kDa (Figure 5A).
PNGase F treatment of live cells led to an approximately 3-fold increase in R4-ICD
levels, particularly in HuCCT FGFR4 cells (Figure 5B). These data suggested that
FGFR4 processing to R4-ICD was enhanced when N-linked glycans were removed.
HuCCT1-FGFR4 cells treated with NGI-1 (an inhibitor of
oligosaccharyltransferase) showed a concentration-dependent loss of glycosylation
(Figure 6A). When cells were treated with 10 μM NGI-1, there was a partial reduction of
glycosylated FGFR4, and R4-ICD levels increased (Figure 6A). At 100 μM NGI-1,
glycosylation of FGFR4 was blocked completely, R4-ICD was not increased, and cells
were sensitized to TRAIL-induced apoptosis (Figure 6A, B). Control cells (those not
treated with TRAIL) also showed increased cell death with 100 μM of NGI-1, suggesting
some drug toxicity. HuCCT-FGFR4 cells were next treated with kifunensine, an inhibitor
of mannosidase I (Figure 6C). This inhibitor will prevent trimming of mannose residues
and prevents subsequent maturation of N-linked glycans. At 8 hours of kifunensine
treatment, there was a partial reduction of the complex-type glycoform of FGFR4 and
increased R4-ICD levels, reminiscent of the effects of 10 μM NGI-1. By 16 hours of
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Actin
37

Untreated PNGase F

HuCCT FGFR4

Figure 5. PNGase F increases R4-ICD levels in cells
A. KMCH and HuCCT1-FGFR4 cells were treated with PNGase F in the culture
medium. B. R4-ICD-to-full-length FGFR4 (percent) was averaged from untreated
and PNGase F-treated HuCCT1-FGFR4 cells. Banding between 30 and 50 kDa was
considered R4-ICD and banding between 85 and 115 kDa was considered full
length FGFR4. Total sample number quantified is indicated on graph. n=5. ***
indicates p <0.001.
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Figure 6. NGI-1 and kifunensine treatments reduced FGFR4 glycosylation and
cytoprotection.
A. HuCCT1-FGFR4 cells were treated with vehicle (“V”) or NGI-1 overnight, at the
indicated concentrations. n=3. B. Caspase activity was measured on HuCCT1FGFR4 cells treated overnight with NGI-1 followed by a 6-hour treatment with 10
ng/mL TRAIL. Quadruplicate samples measured, repeated twice; representative
data shown. * indicates p<0.05. C. HuCCT-FGFR4 cells were treated with
kifunensine, 5 μM, for 0-16 hours. R4-ICD levels increased at 8 hours, and 110 kDa
FGFR4 was absent at 16 hours. A and B were performed twice and C was
performed three times.

51

kifunensine treatment, the 110 kDa FGFR4 band disappeared, and R4-ICD levels were
low. Both these data are reminiscent of the effects observed with PNGase F (Figure 3),
where reduced FGFR4 glycosylation increased levels of R4-ICD, suggesting that the
process of FGFR4 deglycosylation or partial glycosylation promoted processing, but that
completely deglycosylated FGFR4 did not promote processing.
To promote FGFR4 processing to R4-ICD in the absence of protein synthesis
and glycosylation changes, crude lysate was obtained (termed active lysate) and either
frozen immediately or incubated at 37°C to allow endogenous proteases to act.
Processing of FGFR4 to R4-ICD occurred with incubation, and at least twice as much
R4-ICD was seen in cells expressing wild type FGFR4 after a 1 hour incubation of active
lysates (Figure 7A, B). Initial experiments using HuCCT1-FGFR4 cells were performed
to determine if 20- or 60-minute incubation was required, and both were adequate. We
tested processing to R4-ICD in active lysates of cells expressing mutant forms of FGFR4
to understand the role of each of the five glycosylation sites on proteolysis. This
approach, in part, would allow us to determine if increased processing upon
deglycosylation was due to glycosylation of FGFR4 or of another protein. Cell lines
expressing the following forms of mutant FGFR4 were used: N112Q, N258Q, N290Q,
N311Q, N322Q, and quadruple mutant 4Q (only 322 remained an asparagine). Two or
three clones per FGFR4 mutant were used to account for clonal variation. Results were
quantified and graphed as the ratio of R4-ICD to FGFR4 (Figure 7B). Blots used for
quantification are shown in Figure 7C-H. Note the shift in molecular weight for FGFR4
mutants N258Q and N290Q compared to wild-type (Figure 7D, E). Wild type FGFR4
showed the highest amount of processing, and the N290Q mutant showed limited
additional processing to R4-ICD. Mutant 4Q also showed no additional processing. Most
glycomutants showed only a subtle decrease in processing (Figure 7B). In addition, it
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Figure 7. Mutation of selected glycosylation sites reduced processing of
FGFR4 to R4-ICD.
A. Active cell lysates for KMCH and HuCCT1-FGFR4 cells were either frozen
immediately or incubated at 37°C for 1 hour. n=5. B. Active lysates of cells
expressing glycosylation mutants of FGFR4 were incubated at 37°C to measure
processing to R4-ICD. Three selected clones for each mutant (except N322Q
where we had two clones) were averaged. R4-ICD/FGFR4 ratio is graphed. C-H.
Active lysates from the mutant-expressing clones are shown. Samples were either
frozen immediately after lysis (-), or they were incubated for 20 minutes at 37°C (+).
Descriptions of cell lines containing mutant FGFR4 follow: N112Q-expressing cell
lines were 5B1, 5A2 and 5A3. N258Q-expressing cell lines were 3A4, 3B2 and 3B1.
N290Q-expressing cell lines were 7C3, 7C4 and 7A4. N311Q-expressing cell lines
were 8B1, 8A3 and 8A1. N322Q-expressing cell lines were ORIG and 2B2. 4Qexpressing cell lines were 9B2, 9C3 and 9B4.
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appeared as though basal R4-ICD levels were somewhat elevated in the cells
expressing mutant FGFR4 compared to wild-type. This could be due to reduced steric
hindrance, allowing for easier initial S1 cleavage and may ultimately help to explain why
the relative change in processing between frozen samples and those incubated for 20
minutes was reduced in the cells expressing mutant FGFR4 compared to wild-type.
Thus, while deglycosylation in the whole cell increased R4-ICD formation, we could not
replicate this effect with FGFR4 glycomutants.
We considered that glycomutants may not be trafficked properly. Figure 8A
shows a representative anti-FGFR4 immunofluorescence image of several control cell
lines: cells expressing FGFR4 through stable transfection with cDNA (top two panels;
HuCCT-FGFR4) or two separate cell lines with endogenous expression of FGFR4
(bottom two panels; KMCH and Mx-ChA-1). In both exogenously (cDNA transfection)
and endogenously expressing cells, we observe positive cytoplasmic staining for
FGFR4. The top two images in Figure 8A represent two different layers of imaging in
the z plane for a single cell (0.6 μM difference between two images) and allow for better
visualization of FGFR4 localization at the plasma membrane in the upper right image
(see arrows). Images collected from cells expressing mutant FGFR4 are shown in
Figure 8B. In cells expressing wild-type FGFR4, staining appeared not only at the
plasma membrane but also distributed intracellularly. Cells expressing N258Q, N290Q,
N311Q, or N322Q resembled the wild-type FGFR4 distribution. In cells expressing the
N112Q mutant, intracellular FGFR4 showed a region of concentrated staining adjacent
to the nucleus (Figure 8B). In the 4Q cells, intracellular, irregular staining was more
intense than wild-type FGFR4 (but not concentrated in a single region). We performed
dual immunofluorescence on N112Q and 4Q mutant cell lines for FGFR4 and a Golgi
marker, giantin. Figure 8C shows a representative image of each cell line in addition to
KMCH and Mz-ChA-1 cells, which both have endogenous expression of FGFR4. In cells
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Figure 8. Cellular localization of FGFR4
A. Cells expressing exogenous FGFR4 (HuCCT FGFR4) and cells expressing
endogenous FGFR4 (KMCH, Mz-ChA-1) were stained for FGFR4 (white). The top
two panels of HuCCT FGFR4 cells demonstrate FGFR4 staining at the plasma
membrane (near coverslip) and in the cytoplasm (+600 nm). B.
Immunofluorescence of cells expressing mutant forms of FGFR4 were stained to
look for FGFR4 localization. C. Immunofluorescence for both FGFR4 (red) and
giantin (green), with nuclei visualized by DAPI (blue), was performed on cells
expressing wild type FGFR4 and mutants N112Q and 4Q. Bar = 10 µm.
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expressing N112Q-FGFR4 only, FGFR4 appeared to co localize with giantin (yellow). In
these images, FGFR4 is largely observed in the cytoplasm. However, it
can be observed at the plasma membrane, particularly when performing a z-stack and
looking at different layers of the cell (Figure 8A)
We next tested if any of the cells expressing FGFR4 glycomutants showed
altered cell migration or resistance to cell death. All of the clones supported migration
similar to wild type FGFR4. A single clone of the N112Q mutant (5A3) showed
significantly reduced migration compared to a single clone each of N258Q (3B3) and
N311Q (8A3). No additional statistical differences were observed. Thus, each mutant
was capable of promoting a similar migratory effect as wild type (Figure 9).
Next, we tested the ability of FGFR4 to protect cells from apoptosis. Caspase activity
was measured after challenge with chemotherapeutics or staurosporine. Parental
HuCCT1 cells lacking endogenous FGFR4 were sensitive to apoptosis (Figure 10A, B).
Wild type FGFR4 efficiently protected cancer cells from chemotherapy-induced
apoptosis. Cell lines expressing mutant FGFR4 were mostly protected from
chemotherapy-induced cell death compared to HuCCT1 parental cells, but to a lesser
extent than wild type FGFR4. The N322Q mutation showed the least protection, with the
4Q mutant also providing less cytoprotection (Figure 10A). In staurosporine-treated
cells, mutant cell lines expressing FGFR4 N322 or 4Q did not provide any statistical
survival benefit to cells compared to parental HuCCT1 cells. Overall, most of the
glycomutants offered at least partial cytoprotection. A summary of the results is shown in
Table 2.
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Figure 9. Migration and apoptosis of cells expressing FGFR4 glycomutants.
A. Two clones for each mutant were tested for migration over 24 h by transwell
assay. n=3, mean ± SEM. No clones showed a statistically significant difference from
wild type; however there were several statistically significant differences between
clones. These differences are highlighted by letters above each bar. Any bars that
share a letter are not statistically different from one another (ANOVA with Bonferroni
post hoc).
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Table 2.
Summary of the glycomutants and their effects on R4-ICD production, cell migration,
and resistance to apoptosis. The degree of each activity observed is indicated on a
relative scale from zero to 3+.

61

Discussion
FGFR signaling has received increased attention in cholangiocarcinoma with the
identification of FGFR2 fusion mutations that are more common in this tumor type. Other
FGF receptors have the potential to promote malignant signaling, and this study
examined FGFR4. Data in this manuscript primarily relate to how glycosylation regulates
the processing, function, and localization of FGFR4. We demonstrate that non-specific
deglycosylation or blocking of glycosylation increased processing of FGFR4 to a
proteolytic fragment, R4-ICD. Individual and combined glycomutants of FGFR4 did not
recapitulate this increased processing, suggesting the effect is not due to
deglycosylation of FGFR4 itself. All mutants supported cell migration while selected
mutants were less efficient at protecting from apoptosis. Overall, these data show that
glycosylation helps to regulate the processing, signaling, and localization of FGFR4 in
cholangiocarcinoma cells. Each of these roles will be discussed here.
Understanding N-linked glycosylation of proteins requires defining several terms.
Core/high mannose-type N-glycans are added to an asparagine residue in the
endoplasmic reticulum and contain only terminal mannose sugars attached the Nacetylglucosamine (GlcNAc) core. Hybrid-type N-glycans are produced in the Golgi and
are made up of unsubstituted mannose chains and GlcNAc linkages off of the GlcNAc
core. Terminal/complex-type glycans are mature glycosylation patterns that are
generated in the Golgi through trimming high-mannose glycan structures followed by
subsequent addition of other sugar residues, often with sialic acid residues at the
termini. The complex-type glycans are the most common form seen on secreted and cell
surface proteins [131, 132].
Processing of FGFR4 to R4-ICD has only recently been recognized, and the
product corresponds to the kinase domain, separated from the regulation of the ligand-
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binding region. We showed R4-ICD production from endogenous (KMCH) and
transgenic FGFR4 and that R4-ICD is the predominant form of FGFR4 in human
cholangiocarcinoma tumor samples. The rationale for studying the role of glycosylation
in FGFR4 processing is two-fold. First, Notch signaling (a proteolysis-driven event) is
regulated by receptor glycosylation [63]. Complex-type glycosylated FGFR4 was
identified as the functional form for regulating cholesterol biosynthesis [62]. Second,
activation of FGFR3 was necessary for its cleavage [22]. From here, we reasoned that
FGFR4 glycosylation may influence receptor activation and subsequently R4-ICD
production. Indeed, we observed increased R4-ICD with deglycosylation.
Removal of N-linked sugars or inhibition of N-linked glycosylation promoted
processing of FGFR4 to R4-ICD. This increased processing was seen in conditions of
indiscriminate deglycosylation (PNGase F treatment of cells or incubation with inhibitors
of glycosylation). Targeted genetic inhibition at individual sites on FGFR4 did not show
this increase. FGFR4 with each predicted Asn mutated was tested for processing to R4ICD. R4-ICD was observed in cells expressing mutant forms of FGFR4, at some level.
However, additional processing in the incubated samples was not strong (N290) or was
absent (4Q) in two mutants. These data indicated that processing was slower in the
N290Q and 4Q mutant cells (and somewhat slower in N112Q, N258Q, N311Q, and
N322Q). It still occurs, as R4-ICD is seen in cell lysates from all mutant cell lines at time
zero, but loss of glycosylation may reduce the sensitivity to protein cleavage. This
reduced processing efficiency was revealed in the active lysate assay when we imposed
a time constraint. Importantly, we did not find that a specific glycosylation site was
responsible for processing, despite seeing more R4-ICD after deglycosylation of proteins
in the cell. Still, with five potential glycosylation sites, there are 32 potential glycosylation
mutant combinations; our experiments included seven of these. It remains plausible that
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a particular pattern of glycomutants could demonstrate increased processing.
Additionally, it should be noted that we attempted to produce cells expressing a 5Q
mutant form of FGFR4 multiple times, but each time we were unsuccessful.
Regarding signaling, FGFR4 promoted cancer cell survival. In general,
glycosylation mutants of FGFR4 were less cytoprotective than wild type FGFR4.
However, cells expressing mutant FGFR4 were still more protected than cells lacking
FGFR4. The two mutants that provided the least protection were N322Q and 4Q. These
two mutants have mirror image effects on glycosylation—N322Q can be glycosylated at
all sites except Asn-322, while 4Q can only be glycosylated at position 322. The
observation that these two mutants had the least protection from cell death suggests that
position 322 dominated the survival signaling and to match the defect in cytoprotection it
required that all other glycosylation sites be changed. Glycosylation at position Asn-322
may be a strong determinant of survival function. One possible explanation for this high
dependence upon glycosylation at position 322 relates to its proximity to FGFR4’s
transmembrane domain, amino acids 370-390, affecting conformational signaling to the
intracellular domain. Alternatively, it is possible that glycosylation at Asn-322 facilitates
ligand binding.
Our studies on apoptosis relied on caspase activation as a marker and compared
the amount of caspase activation upon induction of apoptosis between cell lines. An
alternative interpretation might consider the magnitude of caspase activation from
untreated to treated conditions, determining fold-change in caspase signal. This
alternate approach still indicated that the N322Q mutant was least protective. Examining
fold of caspase activation indicated that N290Q, N311Q, and 4Q mutants all had similar
protective effects that were impaired compared to wild type. Thus, there were no
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dramatic differences in interpretation of the results when using fold change versus total
magnitude of caspase signal in treated cells, so we relied on the latter.
Modifying the glycosylation of FGFR4 had some effect on localization in the
N112Q and 4Q mutant cell lines. In cells expressing N112Q FGFR4, we observed some
staining for FGFR4 that colocalized at or near the Golgi. Notably, in all cells, FGFR4
immunofluorescent signal was not confined to the plasma membrane. This distribution
may reflect insufficient immunofluorescence signal from the membrane-bound full-length
receptor as well as the processed R4-ICD (potentially freed from the membrane
fraction), or may indicate FGFR4 present on the network of membrane vesicles within
the cell. Previously published FGFR4 immunofluorescent images in cultured cells also
showed that FGFR4 staining did not predominantly localize to the limiting plasma
membrane [133].
Despite initial data that showed that reduced glycosylation of FGFR4 might
enhance processing to R4-ICD, our glycomutants did not support such direct regulation.
Our subsequent studies on proteolytic regulation and regulation of apoptotic signaling
(see Chapter 4) help define the mechanisms of R4-ICD production and its significance in
cancer signaling in cholangiocarcinoma.
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CHAPTER 4: FGFR4 cleavage by ADAM10 and γ-secretase
produces R4-ICD, a functional intracellular kinase.
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Abstract
Fibroblast growth factor receptors make up a family of four receptor tyrosine
kinases that respond to signaling through fibroblast growth factors. One of these
receptors, fibroblast growth factor receptor 4 (FGFR4), has been shown to be
overexpressed in cholangiocarcinoma and linked with a poorer overall prognosis among
patients. We also found that a smaller-than-predicted form of FGFR4 predominated in
human cholangiocarcinoma samples. In the current chapter, we determined whether
FGFR4 was able to undergo regulated intramebrane proteolysis, an event in which the
intracellular domain is cleaved away from the remaining portion of the receptor. We
demonstrated through shRNA knockdown of FGFR4 and stable transfection that FGFR4
intracellular domain (R4-ICD) was a product of FGFR4 cleavage. R4-ICD was more
stable than full-length FGFR4. Production of R4-ICD was reduced through inhibition of
FGFR4, suggesting responsiveness to signaling. Cells transfected to express just R4ICD retained signaling and apoptosis resistance seen with full length FGFR. We used
small molecule inhibitors and genetic inhibition of proteases to determine the proteases
involved in R4-ICD production and showed that FGFR4 could be cleaved to R4-ICD by
ADAM10 and γ-secretase.
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Introduction
Cholangiocarcinoma is a primary cancer of the epithelial cells lining the biliary
tract (cholangiocytes). This cancer is associated with a poor prognosis and
approximately a 10% five-year survival rate [1]. Typical cholangiocarcinoma diagnoses
occur somewhat late in tumor development and progression, since early stages of the
disease often have few or no symptoms. Even with an early diagnosis, patient prognosis
is still quite poor. While new treatments are being developed, many of them target
specific mutations or can only be used in a subset of patients. As such, the best first line
systemic treatment has not been established by clinical trials, though a platinumcontaining chemotherapeutic plus gemcitabine outperformed gemcitabine alone [6].
One field of recent expansion is in the area of drugs targeting receptor tyrosine
kinases (RTKs). This class of medication has been tested in numerous clinical trials and
is currently FDA-approved for cancer therapy. Receptor tyrosine kinases are a group of
58 different proteins that contribute to diverse physiologic and disease processes.
Structurally, these proteins are type I transmembrane proteins, consisting of an
extracellular N-terminal ligand-binding domain, a single pass transmembrane domain
and a C-terminal kinase domain (for example, see Figure 3A). Briefly, signaling usually
occurs first by receptor-ligand interaction. Once ligand has bound, receptor dimerization
can occur, which facilitates kinase domain transphosphorylation and subsequent
downstream signaling [7, 10]. Recent studies have also shown that RTKs can signal
through a process called regulated intramembrane proteolysis (RIP). In RIP, a
sheddase, or protease with the ability to cleave the extracellular domain of the receptor,
removes most of the ectodomain of an RTK, leaving a short extracellular stub. This initial
cleavage event, S1, is followed by γ-secretase-mediated cleavage in the
transmembrane-spanning domain, which releases the intracellular domain (ICD) from
the plasma membrane. From here, there are several fates for the ICD, including

68

translocation to the nucleus (in the case of ERBB4, FGFR3, PTK7 and RYK) [21-24],
localization to mitochondria (ERBB4) [25, 26], phosphorylation of membrane receptors
(EPHB2) [27], initiation of cancer cell repulsion (EPHB2) [28], or simply degradation [30].
Screening of 45 human RTKs as potential γ-secretase substrates confirmed nine
previously known γ-secretase substrates and discovered 12 previously unknown
substrates, including FGFR4 [80]. Specifically, the cleaved ICD for FGFR4 was
determined to be approximately 45 kDa (see supplemental data from the reference).
FGFR4 kinase inhibition has been considered as a therapeutic approach in
cancer with recent clinical trials for the treatment of hepatocellular carcinoma. The
discovery of FGFR4 signaling in other cancers, like breast, lung, gastric cancers,
rhabdomyosarcoma, nasopharyngeal carcinoma, and cholangiocarcinoma, may lead to
additional clinical trials [67, 68, 71, 74]. In the context of cholangiocarcinoma, FGFR4
has been shown to be overexpressed in most patients (Phillips et al., 2021, in review;
see chapter 3). In addition, findings by Xu et al. showed that FGFR4 protein expression
correlated with poorer prognosis in patients with cholangiocarcinoma [68]. Like FGFR1
and 3, there is limited data supporting FGFR4 as a substrate for RIP. Our studies
showed that this proteolytically processed form of FGFR4, termed R4-ICD, is abundant
in human cholangiocarcinoma tumor samples and was the predominant form detected
(Phillips et al., in review; see chapter 3). At this point, however, no studies have
determined the function of the FGFR4 intracellular domain (R4-ICD). Here, we
demonstrate that R4-ICD maintains signaling capacity in cholangiocarcinoma cells.
Further, we identified ADAM10 and γ-secretase as likely candidates to be the proteases
that act on FGFR4 to produce the constitutively active R4-ICD.
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Results
On separation via polyacrylamide gels, full length FGFR4 migrated as two
dominant bands; one at 110 kDa and one at 90 kDa. We have previously demonstrated
both are glycosylated proteins (see Chapter 3). In addition, faster migrating forms were
observed around the 45-50 kDa mark, collectively termed R4-ICD (Figure 11, see also
Figure 4B, Chapter 3, KMCH and HuCCT-FGFR4). To confirm that the 45-50 kDa
polypeptides reflect authentic FGFR4 forms, we used an shRNA approach to deplete
FGFR4. In cells stably transfected to express one of two shRNAs against FGFR4 (419
and 510), full length FGFR4 protein was reduced 43-97%. The 45-50 kDa FGFR4 signal
decreased by 86-96% in the same samples. This demonstrated that both full length and
R4-ICD forms of FGFR4 were sensitive to shRNA targeting FGFR4 mRNA, though we
note a limitation in that the actin signal was also lower in the knock down cells. In
addition, phosphorylated AKT levels were reduced when FGFR4 was knocked down
(Figure 11), demonstrating that FGFR4 signaling was a principal means by which AKT
was activated in KMCH cells.
Conversely, HuCCT cells normally lack FGFR4 protein and showed both full
length and R4-ICD forms upon transfection with an expression plasmid containing the
FGFR4 cDNA sequence (Figure 3B, chapter 3). The R4-ICD protein from endogenous
expression (in KMCH cells) matched the migration of R4-ICD in FGFR4 transfected cells
(HuCCT-FGFR4). Thus, based on immunoreactivity, reduced signal on knockdown,
increased signal on enforced expression, and apparent migration, we identify these
faster migrating 45-50 kDa bands as forms of FGFR4, termed R4-ICD. Because cDNA is
not a substrate for splicing, we reasoned that our observation of R4-ICD in HuCCTFGFR4 cells (transfected with FGFR4 cDNA) does not represent a splice form and may
be due to proteolytic processing of FGFR4 protein.
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Figure 11. Stable knockdown of FGFR4 in KMCH cells.
KMCH cells were stably transfected to express either of two shRNAs targeting
FGFR4 mRNA (419.E8 and 510.F4). Knockdown was achieved in both clones with
the 510.F4 shRNA able to knock down FGFR4 expression by more than 90% (left
panel). Control cells in the left panel were stably transfected with an shRNA to green
fluorescent protein (GFP). Parental KMCH were additionally included in the right
panel. Phosphorylated AKT (Thr-308) is abbreviated pAKT and total AKT as tAKT.
This experiment was performed three times.

71

To assess the function of R4-ICD, we generated clones of HuCCT cells that
stably express a pCDNA 3.1-Flag-HA plasmid encoding amino acids 391-802 of FGFR4
(numbering based on the RefSeq NM_002011.5) after an N-terminal Flag/HA tag. From
HuCCT cells that lack FGFR4, we generated empty-vector transfected cells (EV), cells
expressing wild type FGFR4 (HuCCT-FGFR4), and cells expressing amino acids 391802 of FGFR4 (R4-ICD; Figure 3B). HuCCT-FGFR4 cells had both full length FGFR4
and R4-ICD that migrated similarly to endogenous FGFR4 and R4-ICD in KMCH cells.
Plasmid-generated R4-ICD migrates slower than endogenous R4-ICD, likely due to the
N-terminal epitope (Hemagglutinin, Flag tags) (data not shown). Clones of HuCCT
expressing R4-ICD were named PB1, C3, and C6, and each demonstrated increased
phosphorylation of AKT compared to empty vector cells (Figure 12A, B). Thus, R4-ICD
appears to retain the ability to increase AKT phosphorylation even in the absence of
ligand-binding capacity (constitutive activity).
AKT promotes cholangiocarcinoma cell survival [134], so we tested apoptosis
resistance in cells expressing R4-ICD. HuCCT cells with empty vector (or parental, not
shown) were susceptible to apoptosis upon treatment with the death receptor ligand
TRAIL. Several independent empty vector HuCCT cells (EV-9, EV-G3, and EV2 shown)
showed similar sensitivity to apoptosis. PB1 cells were the first clone generated and
were highly resistant to TRAIL-induced apoptosis (Figure 12C). Subsequently, we
generated C3 and C6 clones that also showed resistance to TRAIL-induced apoptosis
(Figure 12D). Thus, expression of the intracellular kinase domain of FGFR4, similar to
R4-ICD, is sufficient to activate downstream AKT signaling and to protect cells from
apoptosis, similar to full length FGFR4.
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Figure 12. Stable expression of R4-ICD in HuCCT cells.
HuCCT cells lacking endogenous expression of FGFR4 were stably transfected to
express amino acids 391-802 of FGFR4 in order to mimic the FGFR4 intracellular
domain. Stable HuCCT clones expressing R4-ICD were generated and named PB1 or R4-ICD C3 and C6. Expression of this domain was observed as a single band
at about 49kDa (PB-1, panel A) or as a single 49 kDa band with additional faster
migrating fragments (C3 and C6 clones, panel B). Phosphorylated AKT (Thr-308) is
abbreviated p-AKT. (C) Apoptosis was assayed by caspase 3/7 activity in HuCCT
cells (empty vector or R4-ICD PB-1). Empty-vector cells (EV-9 and EV-G3) were
susceptible to apoptosis upon TRAIL treatment (50 ng/mL, 6 hours). *** indicates
p<0.001 versus vehicle-treated (Veh) cells; n.s. = not significant. (D) Apoptosis was
similarly assessed in C3 and C6 clones expressing R4-ICD in HuCCT cells and
empty-vector cells (EV2) were more sensitive than any of the three R4-ICDexpressing cells. This experiment was performed one time. *** indicates p<0.001
versus TRAIL-treated EV2 cells. For all panels, statistics were performed by
ANOVA with post hoc Bonferroni correction.
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With evidence for R4-ICD function in cholangiocarcinoma cells, and high
amounts of R4-ICD in human tumor samples (Phillips et al., 2021, in review; see Figure
3C), we next sought to determine the stability of R4-ICD. Cycloheximide, an inhibitor of
protein synthesis, was employed here for testing the stability of FGFR4 and R4-ICD. By
terminating new protein synthesis, the stability of existing protein could be approximated
in terms of half-life. Specifically, the 110 kDa form of FGFR4 was examined, because
this form of the protein has been previously demonstrated to be the mature complextype glycoform (Phillips et al., 2021, in review; see Figures 4A, 5A) and involved in
signaling [62]. Figure 13 shows an immunoblot from KMCH cells treated with
cycloheximide for up to 6 hours. This experiment was performed four independent times
and each time showed that 110 kDa FGFR4 had the shortest half-life, followed by R4ICD. The calculated half-lives are included in the figure and show that R4-ICD is more
stable than full-length FGFR4.
In characterizing R4-ICD, we next used differential centrifugation to determine its
localization within cells. Cells were lysed in hypotonic buffer, and the nuclear pellet was
collected. The post-nuclear supernatant was then separated into soluble and membrane
fractions by centrifugation. Fractions (nuclei, cytoplasm, and membranes) were then
analyzed by immunoblot (Figure 14). The membrane fraction contained the majority of
FGFR4 and R4-ICD. (Note that we did not endeavor to distinguish the plasma
membrane from intracellular organelle membranes). In addition to membrane
localization, detectable amounts of both full length FGFR4 and R4-ICD were present in
both the cytoplasmic and nuclear fractions. Closer examination shows that the 45 kDa
R4-ICD band in the membrane fraction appears to consist of at least three bands (see
cytoplasmic and nuclear fractions). We have routinely observed multiple bands in the
range of 45-50 kDa as well as additional faster-migrating forms (see Fig. 1B, 2C, 3A, 5A,
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Figure 13. Half-life of full length FGFR4 and R4-ICD.
KMCH cells were treated with cycloheximide, 20 μg/mL, for zero to six hours (time
indicated above each lane). Analysis by immunoblot showed that full length FGFR4
levels were decreased markedly at 1 hour and beyond, especially the mature 110
kDa glycoform. The 90 kDa full length form was more stable. R4-ICD showed loss of
signal by 4-6 hours. R4-ICD half-life is more than double the half-life of FGFR4 110
kDa. This experiment was performed four times, and half-life calculated from the
decay constant, modeling exponential decay. From these four experiments, the
average half-life was determined for 110 kDa and for R4-ICD forms. Actin did not
show decreased protein levels over this 6-hour experiment, consistent with its long
half-life in cells.
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Figure 14. Cellular localization of FGFR4 and R4-ICD.
Differential centrifugation of lysate from KMCH cells was performed to identify the
cellular localization of FGFR4. Full length FGFR4 and R4-ICD were primarily
localized to the membrane fraction; however, detectable amounts of both were
observed in the cytoplasm and nuclear fractions. R4-ICD in the cytoplasmic and
nuclear fractions demonstrate three different bands corresponding to the highest
molecular weight band in lane 1. Experiment repeated three times.
Markers were used to confirm separation of cellular fractions: membrane (giantin),
cytoplasm (GAPDH) and nuclear (Histone H3).
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5C-H, 9, and 11). This complexity will partially be discussed and resolved in figures to
come.
Next, we sought the protease(s) responsible for R4-ICD formation. First, an initial
screening was performed using several protease inhibitors. Inhibitors that were initially
included targeted γ-secretase, granzyme B, or MMPs. These inhibitors and targets were
specifically chosen based on previous studies of RTK cleavage. FGFR1 and FGFR3
have been shown to undergo receptor cleavage events where full-length receptor is
processed to a smaller intracellular domain. FGFR1 was cleaved by MMP2 [39] and
granzyme B [40]. FGFR3 underwent RIP with sequential cleavage by an unidentified
sheddase followed by cleavage by γ-secretase [22]. Thus, we tested if one or more of
these proteases may be involved in FGFR4 processing. Data showed increased rather
than a decrease in R4-ICD levels, especially the largest form, following treatment with γsecretase inhibitor IX (GSI IX) and no dramatic change with granzyme B inhibitor (GBI)
treatment. No apparent changes to R4-ICD were seen in OPA (ortho-phenanthroline,
MMP inhibitor) treatment (Figure 15). An explanation for this data could be that γsecretase is involved in processing of high molecular weight R4-ICD to lower molecular
weight R4-ICD. Because our goal was to determine how R4-ICD is produced and the
function it serves, we further pursued γ-secretase. In our experiments to determine
regulation, we found that the amount of R4-ICD in cell lysates was variable based on cell
confluency (more confluent, generally more R4-ICD up to about 85% cell density, data
not shown). However, we also noted that the amount of R4-ICD was variable even when
confluency was controlled. To avoid difficulty interpreting the amount of R4-ICD, we
developed an assay that allowed us to control the time of R4-ICD production. Active cell
lysates, or whole-cell lysates collected through mechanical sheering under nondenaturing conditions in hypotonic buffer, were incubated at 37 degrees C to allow
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Figure 15. Effects of protease inhibitors on FGFR4 processing to R4-ICD.
KMCH cells were treated for 4 or 8 hours with vehicle (Veh), γ-secretase inhibitor IX,
(GSI IX,10 μM), granzyme B inhibitor (GBI, 10 μM), or ortho-phenanthroline (OPA,
100 μM) as a screening to identify proteases involved in cleaving FGFR4 to R4-ICD.
In GSI IX-treated samples, there was increased R4-ICD. In samples treated with
both GBI and GSI IX, low molecular weight R4-ICD increased in signal. This
experiment was performed more than three times.
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endogenous proteases to process FGFR4 to R4-ICD. This allowed a comparison of R4ICD signal from time zero (samples frozen immediately after lysis) to the amount of R4ICD produced after 20-60 minutes of processing. Incubation of this active cell lysate at
37°C allowed for endogenous protease activity to generate R4-ICD in the absence of
new protein synthesis or regulated proteolysis. R4-ICD levels were noticeably increased
in the sample incubated for 60 minutes (Figure 7A and Figure 16), demonstrating
production of R4-ICD. The same results were seen in KMCH cells that endogenously
express FGFR4 and in HuCCT cells transfected to express FGFR4. For subsequent
experiments we routinely employed HuCCT-FGFR4 cells. We reasoned that the lysate
contained active proteases and that FGFR4 was a viable substrate. If production of R4ICD was due to a protease, then heat inactivation of the lysate should prevent
processing to R4-ICD. Indeed, heating active lysate to 95°C for 1 or 5 minutes prior to
incubation at 37°C nearly completely prevented processing to R4-ICD (Figure 16). Thus,
FGFR4 retains the capacity for processing after hypotonic cell lysis and a heat-sensitive
cellular component is necessary for R4-ICD production, consistent with proteolysis.
Next, we used the active lysate assay above to identify protease inhibitors that reduced
R4-ICD amounts. Treating the active lysate with a dual ADAM10/ADAM17 inhibitor
(GW280264x), or an ADAM10 inhibitor (GI254023x) during incubation markedly reduced
R4-ICD production. Treatment with an inhibitor that targets multiple matrix
metalloproteases (MMP’s), ilomastat, did not significantly reduce R4-ICD formation
(Figure 16). In KMCH cells especially, we observed a decrease in the 110 kDa signal
whenever R4-ICD signal increased, suggesting that the mature functional receptor is the
main substrate that generated R4-ICD. The reduction of R4-ICD production with
GI254023X, a selective ADAM10 inhibitor, was at least as good as the reduction seen
with the dual ADAM10/ADAM17 inhibitor, GW280264X. This led us to further pursue
ADAM10 as a protease capable of cleaving FGFR4.
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Figure 16. Screening for inhibitors of FGFR4 processing to R4-ICD.
Active lysates were collected from HuCCT1-FGFR4 and KMCH cells. Lysates were
either prepared for electrophoresis immediately (No incubation) or were immediately
incubated for an hour at 37°C (all other lanes). Prior to incubation at 37 degrees,
samples were heated to 95°C or treated with protease inhibitors, as indicated in the
figure. Reduced formation of R4-ICD was observed in lysates that were heated to
95°C and lysates treated with GW280264X (ADAM10 and ADAM17 inhibitor) or
GI254023X (ADAM10 inhibitor). Ilomastat, an MMP inhibitor, did not alter R4-ICD.
The panels on the left are from the same gel and same film exposure and are
presented with a gap between the “Incubation” and “1 min 95 degrees” samples
because the first two lanes were inadvertently reversed on loading the gel. To keep
the image symmetric with the right panel, the first two lanes are mirror-reversed
horizontally. This experiment was performed one time in each cell line shown above.
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RIP relies on γ-secretase mediated proteolysis following the initial extracellular
cleavage (sheddase) event. We reasoned that ADAM10 was the extracellular sheddase.
When cells expressing FGFR4 were treated with the γ-secretase inhibitor, GSI IX, we
observed an increase in band intensity of the slowest migrating R4-ICD band via
immunoblot (shown above, Figure 15). This is consistent with the pattern found with
receptor tyrosine kinases that undergo γ-secretase cleavage [80].
In support of our data seen with small molecule inhibitors of ADAM10 or γsecretase, we next genetically depleted the proteases from cells using siRNA to
ADAM10 or presenilin 2 (a catalytic subunit of γ-secretase). We demonstrated a 70%
depletion of PSEN2 mRNA with siRNA treatment (Figure 17). Experiments to
demonstrate depletion of ADAM10 mRNA are underway. Active cell lysates of cells
transfected with negative control, siRNA against PSEN2 or siRNA against ADAM10
were then tested for R4-ICD production. R4-ICD signal at 45-50 kDa was reduced when
PSEN2 or ADAM10 was knocked down (Figure 17). In this experiment, we included
both 20 and 60 minute incubations to observe time-dependent processing. Thus,
independent data from small molecule inhibition and genetic depletion showed that
ADAM10 and γ-secretase contribute to R4-ICD formation.
To further test ADAM10’s ability to process FGFR4, recombinant human
ADAM10 (rhADAM10) was added to FGFR4, enriched by antibody pulldown (Figure
18). HuCCT-FGFR4 cells were lysed in buffer containing 1% NP-40 and pulldown of
FGFR4 was performed using protein G beads and mouse primary anti-FGFR4 antibody
that recognizes the FGFR4 C-terminus (Invitrogen). After pulldown, enriched FGFR4
was treated with rhADAM10 for one hour at 37°C and blotted with rabbit anti-FGFR4
primary antibody (Cell Signaling) to avoid detection of antibody heavy chain. In
rhADAM10-treated groups, R4-ICD levels increased with increasing rhADAM10. We
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Figure 17. ADAM10 and PSEN2 knockdown via siRNA affect FGFR4
processing to R4-ICD.
HuCCT-FGFR4 cells were transfected with siRNA targeting Presenilin 2 or
ADAM10. Left panel: RT-PCR for PSEN2 was normalized to 18S rRNA and plotted
as relative expression. NC = non-targeting negative control siRNA. siRNA = PSEN2
siRNA. Data for knockdown of ADAM10 are pending. Right panel: Lysates were
acquired through non-denaturing means and frozen immediately, or incubated for 20
or 60 minutes to allow for processing of FGFR4 to R4-ICD. When PSEN2 was
knocked down, R4-ICD did not increase as much as seen in NC-transfected cells.
When ADAM10 (abbreviated A10 above the blot) was knocked down either with
siRNA #6 or #7, processing to R4-ICD was reduced. Knockdown of PSEN2 for
mRNA quantification was performed in triplicate, and qPCR was performed in
duplicate. Knockdown of PSEN2 or ADAM10 mRNA for immunoblot was performed
at least three times.
** indicates p<0.01 by Student’s t-test versus NC.
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Figure 18. Enriched FGFR4 was cleaved by recombinant human ADAM10 to R4ICD.
HuCCT-FGFR4 cell lysate were used to enrich for FGFR4 protein by antibodymediated pulldown (affinity enrichment). Enrichment for FGFR4 was performed using
Protein G-coated beads and mouse anti-FGFR4 antibody compared to beads only
(no primary), or to beads plus an unrelated antibody (ab control). Beads were washed
six times and then incubated for one hour at 37°C with increasing amounts of
recombinant human ADAM10 (rhADAM10), 22 ng/μL, 44 ng/μL, or 66 ng/μL
(indicated by the shaded triangle above the lanes). Increasing concentrations of
ADAM10 were associated with increasing levels of R4-ICD. Samples were blotted
with rabbit anti-FGFR4 anti-serum for the immunoblot, allowing R4-ICD to be
visualized without interference from the mouse antibody heavy chain. This
experiment was performed three times.
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employed an ADAM10 substrate containing the cleavable peptide sequence Lys-ProLeu-Gly-Leu, a fluorescent 7-methoxycoumarin group, and a 2,4-dinitrophenyl
quenching group. Upon proteolysis, the fluorophore is released from the quencher, and
the degree of proteolysis is indicated by relative fluorescence units. Cell lysates showed
endogenous protease activity that was efficiently ablated by 95°C incubation for one
minute. Partially restored proteolytic activity was demonstrated upon addition of 45 pg of
rhADAM10 (Figure 19). Our data demonstrated that FGFR4 in cell lysates or enriched
by antibody-mediated pulldown is a substrate for cleavage by ADAM10 and the
proteolytic fragment comigrates with R4-ICD. Inhibition of γ-secretase or siRNA
knockdown of ADAM10 impaired processing.
Next, we looked at the effects of receptor activity on processing to R4-ICD.
KMCH cells were treated with pan-FGFR inhibitors PD173074 or BGJ398, or FGFR4selective inhibitor BLU9931 for one to two hours. All inhibitors were able to reduce the
levels of R4-ICD, but BGJ398 and BLU9931 reduced it the most, with only modest
reduction observed in the PD173074-treated groups (Figure 20). Thus, inhibiting FGFR4
kinase activity reduced R4-ICD production. These data are reminiscent of FGFR3
processing, where receptor activation was necessary for RIP to occur [22] and suggest
that FGFR4 activity promotes proteolysis.
As our experiments here showed that R4-ICD activated AKT and reduced
apoptosis sensitivity, we tested if preventing R4-ICD formation could sensitize cells to
apoptosis. Inhibition of ADAM10 alone did not enhance TRAIL-induced apoptosis in
HuCCT-FGFR4 cells. Additionally, combined ADAM10 inhibition and FGFR4 kinase
inhibition did not sensitize HuCCT-FGFR4 cells to TRAIL-induced apoptosis better than
kinase inhibition alone (Figure 21). Thus, while R4-ICD can mimic the functions of the
full-length receptor, preventing processing of FGFR4 to R4-ICD did not reduce apoptosis
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Figure 19. Protease activity of active lysate is reduced through heat and
recovered with recombinant protease.
Active cell lysates from HuCCT parental and HuCCT-FGFR4 cells were collected
and incubated with pentapeptide ADAM10 substrate (Lys-Pro-Leu-Gly-Leu)
containing a fluorescent 7-methoxycoumarin group at one end and a 2,4dinitrophenyl quenching group at the other. Upon cleavage, fluorescence is
increased by separation of the fluorophore and quencher. Endogenous protease
activity of active cell lysate from HuCCT parental (HuCCT Par) or HuCCT-FGFR4
cells (bars 1 and 2, respectively) is compared to protease activity after boiling the
lysate for one minute prior to adding substrate (bars 3-6), without or with addition of
45 pg of recombinant human ADAM10 (Rescue). Boiling reduced endogenous
protease activity by 98.5% (HuCCT) or 97.8% (HuCCT-FGFR4), and rhADAM10
restored protease activity 11.8 fold (HuCCT) or 13.0 fold (HuCCT-FGFR4) when
compared to boiled samples. Experiment performed a single time for each cell line,
shown.
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Figure 20. FGFR kinase inhibition reduced processing of FGFR4 to R4-ICD.
KMCH cells were treated with pan-FGFR or FGFR4-selective inhibitors for 60 or 120
minutes prior to protein isolation. Control indicates the zero time point for each
condition (Veh, vehicle, PD173074, or BGJ398) just before inhibitor addition. The
first three control lanes were run on the same gel and imaged on the same film and
exposure as the middle panel, with shorter time points removed for clarity. The righthand blots are from a different experiment and different gel. Treatment with
PD173074 or BGJ398 for 60-120 minutes reduced R4-ICD amounts in the cells.
Treatment with BLU9931 for 60 minutes also reduced R4-ICD amounts. Images
representative of three experiments.
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Figure 21. HuCCT-FGFR4 cells show increased sensitization to apoptosis with
FGFR4 inhibition, but not ADAM10 inhibition.
HuCCT-FGFR4 cells were treated with the ADAM10 inhibitor, GI254023X and the
FGFR4 inhibitor, BLU993 to sensitize cells to TRAIL-induced apoptosis. Apoptosis
was measured by Caspase 3/7 activity, plotted on the vertical axis. Untreated
HuCCT-FGFR4 cells were relatively resistant to TRAIL-induced apoptosis. Addition
of GI254023X did not increase sensitivity. Previous experiments showed that 1 µM
BLU9931 was at the low-end of the concentrations that could sensitize to apoptosis
(tested 0.03 – 30 µM, not shown), and the sensitization from BLU9931 was
detectable, though small. ADAM10 inhibitor (0,01 – 1 µM) was unable to increase
sensitization to TRAIL. Treatment groups (ADAM10 inhibitor and FGFR4 inhibitor)
were compared to TRAIL-induced caspase activity of untreated group. *** indicates
p<0.001. Statistics done by ANOVA.
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protection by FGFR4. We interpret these findings to indicate that either full length
FGFR4 or R4-ICD is sufficient to promote downstream tumor signaling.

Discussion
The overall findings of this study relate to the proteolytic processing of FGFR4 in
cholangiocarcinoma cells. Here, we demonstrate that R4-ICD is a proteolytic product
from full length FGFR4, R4-ICD has constitutive signaling activity, and R4-ICD is
produced by the action of ADAM10 and γ-secretase. Each of these findings will be
discussed here.
FGFR4 protein expression was assayed in human cholangiocarcinoma tumor
samples. Fourteen tumor samples were collected and probed for FGFR4 by immunoblot.
FGFR4 was observed in a majority of samples; however, most striking to us were the
robust levels of R4-ICD in all 14 samples. R4-ICD was the dominant form of FGFR4 in
these samples (Phillips et al., 2021, in review; see chapter 3, Figure 3B). Multiple lines
of evidence supported R4-ICD being a proteolytic product derived from FGFR4, rather
than a splice form or nonspecific band. We validated the signal as FGFR4 through
several experiments, including shRNA knockdown of FGFR4 (which also resulted in R4ICD knockdown) and transfection of cells with cDNA coding for full length FGFR4 (which
produced R4-ICD signal on immunoblot). Both of these findings were consistent with the
hypothesis that a single or series of proteolysis events produced R4-ICD.
To test the function of R4-ICD in the absence of full-length receptor, we
generated a tagged form of R4-ICD. This R4-ICD mimic was expressed in HuCCT cells
that lacked endogenous FGFR4. R4-ICD behaved similarly to full length FGFR4,
consistent with the kinase domain retaining constitutive activity. Others have shown that
FGFR4 signaling (and receptor tyrosine kinase signaling, in general) is dependent upon
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ligand binding, which has been shown to reduce the effects of the autoinhibitory region,
producing a conformational change in the protein and allowing phosphorylation events at
the kinase domain to occur. R4-ICD, however, lacks a ligand binding domain.
Commercial vendors, including Millipore Sigma, Abcam, and Thermo Fisher Scientific,
sell recombinant human FGFR4. This recombinant FGFR4 consists of the kinase
domain, with molecular weights ranging from 36 kDa to 65 kDa. Data sheets from
vendors confirm activity of recombinant FGFR4 under standard assay conditions and in
the absence of ligand or any other means of activation. These data strongly suggest that
R4-ICD, which is structurally quite similar to these commercial forms, is active
independent of ligand. We anticipate that R4-ICD is constitutively active, though we
cannot rule out an intracellular event that activates R4-ICD in our cell lines without our
intervention. An N-terminally truncated form of FGFR4 has previously been observed in
pituitary tumors that includes the kinase domain on a shortened intracellular protein
lacking the ligand-binding domain [73, 135]. This form resulted from the expression of
FGFR4 via a pituitary-specific cryptic promoter. When this form of FGFR4, termed PTDFGFR4 (pituitary-tumor-derived FGFR4), was transfected into non-malignant GH4
pituitary cells, the cells showed malignant features (large tumor formation, invasion in
mouse models). In contrast, when the same GH4 cells were transfected with empty
vector or full length FGFR4, well-delineated tumor nodules formed and no invasion was
observed, suggesting benign behavior [135]. We interpret these published findings to
demonstrate that an intracellular active FGFR4 kinase, like R4-ICD, promoted tumor
features and lacked regulation seen in the full-length receptor. This further supports the
findings shown here and helps to expand the importance of FGFR4 processing to R4ICD to multiple types of cancer.
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In our experiments looking at R4-ICD levels in human cholangiocarcinoma cell
lines and tumor samples, we were able to consistently observe R4-ICD without the need
to block protein degradation through the 26S proteasome or to inhibit γ-secretase to trap
a proteolytic intermediate. Thus, in our experiments, we were able to demonstrate that
R4-ICD is both stable and functional in cholangiocarcinoma.
As discussed previously, amplification of the FGF19 genetic locus is observed in
over 3% of cholangiocarcinomas [77, 124-126]. Additional data has shown that FGF19
overexpression can promote tumorigenesis [82]. However, our findings suggest that
FGF19 amplification is not necessary in all cholangiocarcinomas, as there is processing
of the receptor to an active, ligand-independent form. It should be noted that ligand
activation of FGFR4 appears to enhance receptor processing to R4-ICD, so increased
ligand may further exacerbate R4-ICD tumor signaling.
Regarding processing of FGFR4 to R4-ICD, current data suggest that activation
promotes the proteolytic events that result in R4-ICD. However, additional studies could
increase the confidence in this finding. Currently, we have only employed small molecule
inhibitors to generate evidence that receptor activity promotes R4-ICD production. Past
studies on FGFR3 have demonstrated that constitutively active receptor was cleaved,
while kinase dead FGFR3 was not, even in the presence of ligand [22]. These data
strongly suggest that it is receptor activation and not ligand binding which promoted
receptor cleavage. Future studies can employ mutationally-active FGFR4 versus kinasedead FGFR4 to test activation-dependent cleavage. We have shown that enriched
FGFR4 is a direct substrate of the extracellular protease, ADAM10, and that proteolysis
leads to increased R4-ICD. We did not attempt to determine the cleavage site or
whether ADAM10 or γ-secretase activity is first in FGFR4 processing. Findings from

90

Merilahti et al. and studies on Notch signaling suggest that ADAM10 may be the initial
sheddase that allows for subsequent γ-secretase-mediated intramembrane proteolysis.
While the data in this study are consistent with a role for both ADAM10 and γsecretase in FGFR4 cleavage to R4-ICD, some limitations exist. HuCCT cells lack
expression of FGFR4. When we stably expressed just R4-ICD in these cells, they
behaved similarly to our stable HuCCT-FGFR4 cell line regarding increased AKT
phosphorylation and increased resistance to apoptosis. In comparing the HuCCT R4ICD and HuCCT-FGFR4 cell lines, one important factor has been the presence of R4ICD in both cell lines. Because R4-ICD is a proteolytic product of FGFR4, cells
expressing FGFR4 and the proper proteases will also have R4-ICD present. As such,
producing an FGFR4-positive and R4-ICD-negative cell line (e.g., only full length
receptor present) is not currently a reasonable goal. Rather, our HuCCT R4-ICD cell line
can be used to understand the role of R4-ICD alone in promoting malignant phenotypes
and comparing them to our HuCCT-FGFR4 and HuCCT parental cells. Using these
three cell lines, we can reasonably determine the role of FGFR4 and R4-ICD in
cholangiocarcinoma tumorigenesis and progression. In order to understand the role of
just full length FGFR4 in our cell lines, we would need to produce an uncleavable form of
FGFR4. Knowing the exact cleavage sites on FGFR4 would be useful prior to attempting
to produce an uncleavable FGFR4. However, this information is not entirely necessary,
as long as we have narrowed down a range of amino acids in which cleavage occurs.
Domain swapping with the juxtamembrane portion of receptors that are not protease
substrates could generate an uncleavable FGFR4. This brings us to our next limitation.
We do not know the exact cleavage sites on FGFR4, and data suggest that the R4-ICD
neo-N-terminus may not be uniform (multiple R4-ICD bands). We suspect this is
because of presenilin’s ability to cleave proteins in a sequence-independent manner and
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anticipate a range in size of R4-ICD products. In our HuCCT R4-ICD PB-1 cells, R4-ICD
is represented by a single band at approximately 50 kDa and is not a product of
proteolysis. In our HuCCT R4-ICD C3 and C6 cell lines, R4-ICD is represented by
several bands between 30 and 50 kDa, of which the slowest migrating band matched the
band seen in the PB1 cell lines. HuCCT R4-ICD cells are stably transfected with cDNA
coding for a tag followed by amino acids 391-802 of FGFR4. This is in contrast to the
multiple R4-ICD bands observed in KMCH and HuCCT-FGFR4 cells, ranging in
molecular weight from 45-50 kDa.
Proteolytic cleavage of FGFR4 in some circumstances could act to reduce
growth factor signaling rather than increase it as we have observed. Indeed, for some
receptors, intramembrane proteolysis leads to receptor degradation. For example, the
antibody datasheet for the Cell Signaling rabbit monoclonal anti-FGFR4 (#8562) shows
FGFR4 in two liver and one colorectal cancer cell line. In both liver cell lines, R4-ICD
forms are obvious. However, the colorectal cancer cell line, Colo-205 lacked R4-ICD.
We speculate these cells (and others like MCF-7 cells) may preferentially degrade
cleaved FGFR4, so the R4-ICD kinase is not stable and active. Thus, in different cancer
types, increased FGFR4 cleavage could result in increased R4-ICD and increased
malignant signaling or in decreased receptor and decreased signaling, dependent on
R4-ICD stability.
Some nuances exist in the processing of FGFR4 in the presence of GSI IX when
compared to processing when PSEN2 is knocked down. In the case of GSI IX, we
observe an increase in R4-ICD. However, siRNA knockdown of PSEN2 caused reduced
levels of R4-ICD. A possible explanation is that GSI IX can inhibit both PSEN1 and
PSEN2 activity. In our siPSEN2 knockdowns, PSEN1 is not inhibited or knocked down.
Under this explanation, γ-secretase containing PSEN1 as the active protease would take
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on a protein degradation phenotype, reducing R4-ICD levels via breakdown, while γsecretase containing PSEN2 as the active protease would have more of a processing
function.
When we attempted to eliminate the production of R4-ICD through chemical or
genetic inhibitors of ADAM10 and γ-secretase, we were unsuccessful. Cycloheximide
treatment of cells suggested the half-life of R4-ICD to be roughly 3.2 hours, and our
inhibition was maintained for up to 4 hours (chemical, GSI IX) or several days (genetic
knockdown of ADAM10, PSEN 2 or both), so it is likely that there was imperfect
inhibition or that other minor proteases were able to compensate.
Overall, this finding of a functional proteolytically released intracellular domain of
FGFR4 is exciting. R4-ICD is characterized here as a new form of FGFR4 that exhibits
constitutive tumor signaling activity.
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CHAPTER 5: DISCUSSION
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Phosphorylation of FGFR4 regulates protein function and cancer signaling
On the topic of post-translational modifications (PTMs), glycosylation may be
second only to phosphorylation in importance for regulating signaling. This dissertation
just touched on phosphorylation of FGFR4 (i.e., Chapter 3, treatment of cell lysate with
lambda phosphatase), but did not add a large amount of data or new interpretations of
receptor phosphorylation. Still, phosphorylation of FGFR4 and the subsequent
downstream pathways are important; numerous studies have been performed to better
understand this key aspect of the receptor tyrosine kinase, and mutations have been
discovered that impact FGFR4 phosphorylation states or phosphorylation of downstream
signaling molecules. FGFR4, like other FGFRs, contains a “split” tyrosine kinase
domain, two domains separated by up to 100 mostly hydrophilic amino acids, known as
the kinase insertion sequence [7, 10]. This kinase insertion sequence for a specific
protein is highly conserved between species. However, this insertion sequence varies
significantly from protein to protein, suggesting that the insert has a functional role that is
receptor-specific. The kinase insertion sequence is believed to play important roles in
RTK interactions with substrates and effector proteins [7]. Regarding phosphorylation
sites, FGFR4 contains multiple potential sites within its kinase domain, including tyrosine
and serine residues. The FGFR4 kinase transphosphorylates the homodimeric FGFR4
binding partner. This FGFR4 phosphorylation is initially catalyzed by Asp-612 (invariant
aspartate) within the conserved histidine-arginine-aspartate motif [136], leading to
phosphorylation of Tyr-642 and Tyr-643 (of the YYKK motif in the activation loop).
Phosphorylation of these two tyrosine residues is necessary for kinase activity and
significantly increases RTK catalytic activity. This YYKK motif and its function is
conserved across FGFRs [137]. The remaining phosphotyrosine residues allow for
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docking of SH2 domain-containing proteins, leading to activation of downstream
pathways [138, 139].
One commonly seen polymorphism that impacts phosphorylation and receptor
signaling is FGFR4 G388R. This form of the protein has been shown to be degraded
less quickly and has increased phosphorylation following ligand binding when compared
to the Gly-388 form of FGFR4 [140]. Residue 388 is located at the C-terminal end of the
transmembrane domain (residues 370-390 span the membrane). In the context of a
G388R, the arginine residue is hypothesized to modify the structure of the
transmembrane region, leading to an additional intracellular STAT3 binding site and
promoting STAT3 phosphorylation [141].
In rhabdomyosarcoma, FGFR4 overexpression or activating mutations (N535K,
V550E, V550L) are frequently observed, with approximately 10% of embryonal
rhabdomyosarcoma patients having an FGFR4 activating mutation [74, 142, 143]. In wild
type FGFR4, residues Asn-535, His-530 and Ile-533 form hydrogen bonds and stabilize
the inactivated form of FGFR4. In N535K, this hydrogen bonding is disrupted, and the
inactive form is destabilized. Val-550 site mutations (V550E and V550L) alter the
gatekeeper site where ATP binding occurs. Mutation from valine to a larger glutamate or
leucine residue results in a larger gatekeeper residue and stabilization of the active
FGFR4 structure [144].
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Glycosylation of FGFR4 regulates protein function and cancer signaling
In chapter 3, N-linked glycosylation of FGFR4 and its implications in protein
localization, processing, cell migration, and apoptosis susceptibility were examined in
depth. Based on the location of putative N-linked glycosylation sites in the ligand-binding
and juxtamembrane regions, we tested the role of N-linked glycosylation on FGFR4
function through enzymatic and genetic manipulations.
The recognition that glycosylation of proteins regulates features of cancer goes
as far back as 1948 when Winzler and Smyth published on the increased levels of
glycoproteins in cancer patients compared to individuals without cancer [145]. Since
then, countless studies looking at glycoproteins in cancer have been published. They
show altered glycosylation patterns in various cancers including prostate, colorectal, and
breast cancers [146-149]. Data showing altered glycosylation of proteins in cancer cells
has translated to the use of certain glycoproteins as cancer biomarkers, or indicators of
disease status. Some examples include cancer antigen 19-9 (CA 19-9) in
gastrointestinal cancers, HER2/neu in breast cancer, haptoglobin in hepatocellular
carcinoma [150, 151] and prostate-specific antigen (PSA) in prostate cancer [146, 152,
153]. Typically, biomarker levels are measured over time; however, their use has been
expanded. For some biomarkers, like PSA or haptoglobin, glycosylation patterns can
help distinguish between the presence or progression of tumor and normal tissue [146,
150, 151].
Notch protein is being investigated as a prognostic biomarker for non-small cell
lung cancer and acute myeloid leukemia [154, 155]. Notch activation has been shown to
drive cell proliferation and transformation to malignancy. In cancer, variations in Fringe
glycosyltransferases also affect Notch signaling [63, 85, 86, 130].
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It is nearly impossible to discuss the field of glycoproteins in cancer without
mentioning mucins. Mucins are large, heavily glycosylated (O-linked and N-linked)
secreted or membrane-bound proteins that make up mucus. Physiologically, they are
produced by epithelial cells at areas exposed to harsher conditions and serve as
lubricants and molecular barriers, allowing tissues to maintain homeostasis. In cancers,
mucins have been hypothesized to play a role in protecting tumor cells from the rather
harsh acidic, hypoxic and protease-rich environment associated with solid tumors, in
addition to acting as a potential barrier against the immune system and
chemotherapeutic agents [156]. Data has shown that glycosylation patterns of mucins
produced by tumor cells differ significantly from the glycosylation patterns of mucins
produced by healthy cells [157-162].
While glycosylation plays a role in the signaling of cancer molecules (Notch) and
the detection and progression of cancer (biomarkers), it can also be used as a target for
cancer treatment. NGI-1 (N-linked glycosylation inhibitor 1) is an inhibitor of
oligosaccharyltransferase (OST), and has been shown to reduce receptor tyrosine
kinase activity in gliomas while sensitizing them to radiation. Because NGI-1 does not
completely inhibit OST, drug toxicities are fairly low [163]. Additional studies showed that
tumor cells are dependent on receptor tyrosine kinase activity (EGFR or FGFR), and
exhibited cell cycle arrest and changes in morphology when they were treated with NGI1 [164, 165]. It was with these data in mind that the N-linked glycosylation of FGFR4 was
targeted as a way to modify receptor signaling and cholangiocarcinoma cell line
phenotypes.
Kifunensine is a natural alkaloid that inhibits mannosidase I in cells, trapping Nlinked glycoproteins in their high-mannose form and preventing trimming and
subsequent modification to complex-type N-glycans. Thus, while NGI-1 blocked the
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addition of N-glycans, kifunensine blocked their maturation. We observed that both NGI1 and kifunensine reduced the amount of complex N-glycosylated FGFR4. When
complex-type glycosylation of FGFR4 was completely prevented (100 μM NGI-1 or 16
hours with kifunensine), this prevented processing of FGFR4 to R4-ICD. However, when
complex-type glycosylation was partially prevented (10 μM NGI-1 or 8 hours of
kifunensine), there was an increase in R4-ICD. These results could be due to direct or
indirect effects of altered glycosylation on FGFR4. If direct, then FGFR4 that has fully
complex-type N-glycosylation is partially resistant to proteolysis. Put another way, partial
removal of complex glycans from FGFR4 increased proteolysis. However, we speculate
that R4-ICD is not produced from high-mannose and hybrid-type N-glycans, so complete
prevention of mature complex-type glycosylation forms of FGFR4 removes the substrate
from which R4-ICD is generated. Because R4-ICD has a longer half-life than complextype glycosylated FGFR4, it was still observed in some experiments when complex
glycosylated FGFR4 was absent. If the effect is indirect, then we hypothesize that either
ADAM10 or γ-secretase function is increased by partial loss of complex-type glycans but
almost completely inhibited by full loss of complex-type glycans.

Proteolysis of FGFR4 regulates protein function and cancer signaling
While alternative splicing of the extracellular immunoglobulin III loop has been
clearly observed and demonstrated in FGFRs 1-3, FGFR4 lacks an alternative exon at
this location, and thus, does not undergo alternative splicing. In FGFRs 1-3, alternative
splicing results in an immunoglobulin III loop that has varying compatible ligands
depending upon which exon is expressed. Alternative splicing of FGFRs is observed in
other parts of the protein structure including at the autoinhibitory domain (FGFR1 and 2)
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[166, 167], Alternatively splicing at the autoinhibitory domain of FGF1 and 2 mRNA
produces a more active receptor and alternative splicing in the transmembrane domain
(FGFR3 and 4) [168, 169] produces a soluble, secreted receptor. While FGFR4 has
been shown to undergo alternative splicing, it is far more commonly observed among the
other FGFRs.
Polyacrylamide gel electrophoresis demonstrated multiple forms of FGFR4. We
were able to explain these by post-translational modifications rather than alternative
splicing. Here, we demonstrate that FGFR4 is a direct substrate of ADAM10 and
proteolysis produced R4-ICD. R4-ICD is stable in cholangiocarcinoma cells and has
signaling function. Merilahti et al. used PMA and γ-secretase inhibitor IX (GSI IX) to
show RIP among receptor tyrosine kinases [80]. In the case of FGFR4 (and other
receptor tyrosine kinases), the cleaved product was only observed when γ-secretase
was inhibited, even when the receptor was being expressed under a strong promoter.
This suggests that γ-secretase-mediated proteolysis may be involved in protein
degradation for FGFR4 in some cells. In our cholangiocarcinoma cells, we observed an
increase in the slowest migrating R4-ICD band when γ-secretase was inhibited,
consistent with Merilahti et al. findings.
Our finding that R4-ICD was stable in cholangiocarcinoma suggests that γsecretase-mediated proteolysis promotes degradation in some cells (e.g., MCF7 cells
used by Merilahti) and not in other cells (e.g., cholangiocarcinoma cells). The R4-ICD
form of the receptor (endogenous N-terminus undetermined or plasmid-driven R4-ICD,
amino acids 391-802) is structurally similar to recombinant human FGFR4 sold for
kinase assays (Millipore Sigma # 14-583, amino acids 442-755 or Thermo Fisher
#P3054, amino acids 460-802). These commercially-available recombinant R4-ICD
mimics have constitutive activity and do not require activation for catalytic activity. Thus,
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we reasoned that intracellular R4-ICD would also have constitutive activity. Data we
currently have show HuCCT R4-ICD cells behaving similarly to HuCCT-FGFR4 cells
with regard to AKT phosphorylation and apoptosis resistance. R4-ICD has been shown
to access different cellular compartments (Figure 14) and promotes cell survival in a
ligand-independent manner (Figure 12). However additional experiments need to be
done to define additional potential biologic functions of R4-ICD.
FGFR proteins undergo dimerization and transphosphorylation in order to
become active. In the case of R4-ICD, we speculate that two R4-ICD molecules can
dimerize and undergo transphosphorylation. It is also reasonable to suspect that R4-ICD
can also dimerize with full length FGFR4. When cells expressing FGFR4 were
fractionated by differential centrifugation, data showed that FGFR4 and R4-ICD primarily
localized with the membrane fraction, with small amounts of the upper R4-ICD band in
the nuclear fraction and small amounts of the lower R4-ICD bands in the cytosol (Figure
14). This leads us to hypothesize that FGFR4 shedding (S1 cleavage event) is not
always followed by γ-secretase cleavage (S2). If this interpretation holds, that the
cytoplasmic R4-ICD form is the product of both sheddase and γ-secretase cleavage and
the nuclear R4-ICD form is the transmembrane-associated product of sheddase activity,
it may be possible for the membrane-bound intracellular domain of FGFR4 to be
internalized and translocated to the nucleus. Finally, the membrane fraction contained
the majority of R4-ICD, including both the upper and lower bands. If R4-ICD dimerizes
with FGFR4 or interacts with other membrane-bound proteins, it would be present in this
fraction as a peripheral membrane protein. This is reasonable to hypothesize, because
R4-ICD contains domains known to bind other proteins. Additionally, it contains a new Nterminus, which may also contribute to binding potential. As such, additional experiments
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must be done before we can determine which, if any, R4-ICD forms act in new cellular
compartments.
Another characteristic of R4-ICD is its prolonged half-life. In cells treated with an
inhibitor of new protein synthesis, we showed that R4-ICD was more stable than the 110
kDa FGFR4 form. The half-life of R4-ICD was approximately two hours longer than that
of 110 kDa FGFR4 (3.20 hours vs 1.24 hours). Since R4-ICD is suspected to no longer
be a transmembrane protein, it is reasonable to hypothesize that it no longer undergoes
the same receptor recycling that FGFR4 and other FGFRs do.

Implications of findings shown here on different fields
Data and findings shown in this dissertation primarily relate to two types of post
translational modifications (glycosylation and proteolysis) on FGFR4 protein signaling in
cholangiocarcinoma. The implications of regulated intramembrane proteolysis on FGFR4
signaling have been discussed here; however, 11 additional RTKs were reported to
undergo RIP [80]. Future studies could lead to the discovery of new proteolytic products
(like R4-ICD) that have the potential to promote malignant phenotypes or play a role in
cancer. Should additional studies show that these cleaved forms of RTKs are involved in
disease states, there may be an additional push to develop drugs targeting γ-secretase
(or presenilin-1 or -2) while minimizing the toxicities associated with past attempts.
Alternatively, researchers may look into targeting the specific sheddases involved in
priming RTKs for RIP. This approach is more targeted and thus, may be associated with
fewer adverse outcomes. Additional studies in other cancers are needed to identify if R4ICD regulates cancer signaling. Observations of immunoblots from pancreatic cancer
cells suggest R4-ICD is present beyond biliary tract cancers.
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Implications of findings shown here on the field of cholangiocarcinoma
Findings shown here may directly impact the field of cholangiocarcinoma and
cholangiocarcinoma treatments moving forward. First, elevated amounts of FGFR4 and
R4-ICD proteins were common and observed in the majority of cholangiocarcinomas.
Thus, relying on RNA or DNA sequencing data will miss altered FGFR signaling in many
cholangiocarcinoma patients. Further, inhibitors that are selective to FGFR1-3 may not
provide patients with the full benefit. FGFR kinase inhibitors have been used to treat
cholangiocarcinomas positive for FGFR2 fusion proteins. However, these fusion proteins
are seen in only 10-15% of cholangiocarcinomas.
Data here showed that FGFR4 and R4-ICD are observed at abundant levels in
>80% of cholangiocarcinomas. Despite the small sample size (n=14), these findings and
other data shown here support the use of FGFR4 inhibitors in cholangiocarcinoma
patients. While knowing the FGFR2 fusion protein status is certainly important and can
provide a rationale for kinase inhibitor use in 10-15% of patients with
cholangiocarcinoma, our data suggests that knowing the FGFR4 status and treating
FGFR4-positive cholangiocarcinomas with kinase inhibitors may be beneficial for a
majority of cholangiocarcinoma patients. We note the caveat that the current studies do
not show that the majority of cholangiocarcinoma tumors are dependent on FGFR4,
simply that this receptor is commonly increased. With FGFR4-selective inhibitors
currently in clinical trials, we may soon see significantly improved outcomes for patients
with cholangiocarcinoma.
Evidence suggests that while the individual glycosylation sites on FGFR4 may
not significantly modify its signaling ability or cell phenotypes, reducing the ability of cells
to perform N-linked glycosylation, as a whole, may hold potential to increase apoptosis
sensitivity in cholangiocarcinoma cells. These data are supported by other published
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findings that showed inhibition of N-linked glycosylation sensitized to radiotherapies
while maintaining minimal toxicities. Overall, FGFR4 in cholangiocarcinoma is expressed
at high levels, is processed via glycosylation and proteolysis, and mediates cancer
signaling.
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